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ABSTRACT 
Endocytosis plays a critical role in the maintenance of cellular homeostasis.  Due 
to its ability to resolve extracellular signals, the endocytic pathway controls many 
cellular processes, including transcription, proliferation, cell migration and cell fate 
determination. One relevant, unanswered, question regarding the role of 
endocytosis in the cell is whether subversion of the endocytic route is involved in 
the development of pathological conditions, such as cancer. This possibility is 
supported by studies showing altered expression of several endocytic proteins in 
human tumors. In a previous study in our lab, the endocytic protein Epsin 3 (Epn3) 
was found in a gene signature prognostic for metastatic breast cancer. Epn3 
belongs to the Epsin family of endocytic proteins. Unlike the other Epsin members, 
Epn1 and Epn2, which are ubiquitously expressed, Epn3 is exclusively expressed 
in gastric cells and in wounded or pathological tissues exhibiting altered cell-
extracellular matrix interactions. While Epn1 and Epn2 have been well 
characterized as endocytic adaptors, the exact function of Epn3 protein in 
endocytosis or signaling is largely unknown. 
 In the present study, we show that Epn3 is overexpressed in approximately 
30% of breast tumors and that upregulation of this protein correlates with clinico-
pathological parameters of aggressive disease.  We also show that EPN3 gene is 
amplified in human breast tumors and that this genetic alteration can occur 
independently from HER2 amplification in these tumors. Through functional 
studies using in vitro and in vivo breast cancer models, we demonstrate that 
breast tumor cells harboring Epn3 amplification/overexpression are dependent on 
Epn3 deregulation for the maintenance of their tumorigenic potential. In agreement 
with a possible oncogenic role, overexpression of Epn3 in a breast tumor cell line 
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increases the tumorigenic potential in vivo. Of note, Epn3 overexpression is also 
able to induce, both in normal and tumor breast cells, transcriptional and 
morphological changes typical of an epithelial-to-mesenchymal transition (EMT), in 
a TGFβ−dependent manner; indeed, Epn3 overexpression induces upregulation of 
TGFβ ligands and receptors and inhibition of TGFβ signaling is able to revert 
Epn3-induced EMT.  In addition, we show that Epn3 increases the capacity of 
normal mammary epithelial cells to form mammospheres in vitro, suggesting that 
Epn3 may contribute to the expansion of the breast cancer stem cell compartment. 
 Finally, we demonstrate that Epn3 is involved in E-cadherin internalization, 
by inducing its downregulation from the cell surface upon TGFβ-stimulation.  
 In conclusion, our data suggest a novel oncogenic role for Epn3 in human 
breast cancer, through its action as an endocytic protein on E-cadherin trafficking. 
Overexpression of Epn3 might enhance E-cadherin internalization, and 
consequently induce EMT activating the expression of mesenchymal proteins that 
promote cell invasion and lead to tumor aggressiveness.  
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INTRODUCTION 
Emerging evidence suggests that endocytosis is a master regulator of cell 
signaling events that controls not only signal attenuation, but also the duration, 
intensity, integration and spatial restriction of the signals [1]. By exerting this 
regulatory role, endocytosis is believed to control many cellular processes 
including transcription, proliferation, cell migration and cell fate determination [2]. It 
is possible therefore that subversion of endocytic pathways could have a role in 
the development and progression of pathological conditions, such as cancer. 
Indeed, the altered expression of several endocytic proteins in human tumors 
argues in favor of such hypothesis (reviewed in [3]).  
We recently uncovered a potential role for the endocytic protein Epsin3 
(Epn3) in breast tumorigenesis. By performing a transcriptional profiling of human 
breast tumors from a cohort of surgical breast cancer patients with complete 
follow-up, we identified Epn3 in a transcriptional signature that is prognostic for 
metastatic breast cancer (our preliminary unpublished data). Increased EPN3 
mRNA levels were detected in 20% of all breast tumors analyzed and this 
percentage increased to 45% in the subgroup of poor prognosis tumors. 
Interestingly, the EPN3 gene is located on the chromosome 17 which also harbors 
the HER2 gene, one of the most clinically relevant and frequently amplified 
oncogenes in breast cancer.  
Based on these initial observations, we hypothesized that Epn3 might be 
involved in the development of breast cancer and designed a study aimed at: i) 
analyzing Epn3 expression in human breast tumors and its association with 
clinico-pathological and prognostic markers in a large cohort of breast cancer 
patients; ii) characterizing the involvement of Epn3 in breast tumorigenesis 
 
 
13 
through functional studies in cell-based model systems; iii) investigating the 
molecular mechanisms underlying such role of Epn3.  
Thus, in this introduction I will provide an overview of the current literature 
relevant to this project: in Chapter 1, I will present evidence arguing for the 
existence of a network between endocytosis, cell signaling and cancer; in Chapter 
2, I will describe what is currently known about Epn3 and the epsin family; finally, 
in Chapter 3, I will explain why the identification of novel markers through genetic 
profiling is a useful approach to advance the clinical management of breast 
cancer.  
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1 The complex network of endocytosis, cell signaling and 
cancer 
1.1 Endocytosis as a master regulator of cell signaling 
Endocytosis has long been viewed as a cellular program through which eukaryotic 
cells internalize nutrients, membrane-associated molecules and viruses. However, 
this is a simplistic and primordial definition of the endocytic process. Recent data 
has shown that endocytosis is a master regulator of signaling circuits, since it has 
the ability to resolve signals coming from the extracellular environment in time and 
space. Indeed, endocytosis regulates signal transduction as well as 
morphogenetic aspects of normal cell physiology, including cell proliferation, cell 
adhesion and migration (reviewed in [1, 2, 4]). 
 
1.1.1 “Who and how”: different entry routes for different cargoes 
Multiple cell entry routes have been identified. Figure 1 illustrates the main 
endocytic pathways studied so far: phagocytosis, macropinocytosis, and 
micropinocytosis (which includes clathrin-dependent endocytosis, caveolin-
dependent endocytosis and clathrin and caveolin-independent pathways). These 
internalization pathways differ in the cargoes they transport and in the protein 
machinery that is involved in the endocytic route. 
Phagocytosis internalizes large particles (> 500nm), including bacteria and 
apoptotic cells [5] while macropinocytosis is responsible for fluid uptake [6]. Both 
processes are characterized by large actin-based rearrangements of the plasma 
membrane (PM) [7]. 
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Figure 1 | Pathways of entry into cells.  
The known endocytic pathways are shown. The major endocytic regulators are 
represented (i.e. actin filaments, clathrin, dynamin, caveolin). The intracellular 
trafficking of internalized molecules is illustrated (i.e. early endosome, lysosome) 
[adapted from [8]] 
 
 
Micropinocytosis is, instead, characterized by smaller invaginations of the 
PM (<200 nm) and comprises clathrin-mediated endocytosis (CME) and non-
clathrin-mediated endocytosis (NCE).  
CME is the most well characterized endocytic pathway. This pathway is 
responsible for the uptake of nutrients, pathogens, growth factor receptors and PM 
associated molecules (reviewed in [9]). PM cargoes are recruited in clathrin-
coated pits (CCPs) and adaptor molecules mediate this process by binding both 
clathrin and protein cargoes [10-12].   
Several accessory proteins have been described to be associated with 
CCPs. The best characterized adaptor protein is the adaptor protein 2 (AP2), as it 
was the first accessory protein to have been described and it is the most abundant 
in cells.  
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Nevertheless, many other adaptors have been proposed to substitute AP2, 
such as Epsin and EPS15  (in the case of internalized epidermal growth factor 
receptor - EGFR [13, 14]) or β-arrestin (in the case of internalization of G protein-
coupled receptors - GPCR [15]).  
 The term NCE is used to refer to a heterogeneous group of pathways that 
are insensitive to clathrin depletion, while they are dependent on cholesterol-rich 
PM domains [8, 16]. The molecular characterization of NCE is still limited and 
currently its classification relies on three major criteria: 1) dependency on dynamin 
for releasing vesicles; 2) presence of “coat-like” proteins involved in the membrane 
curvature, as in the case of caveolin-mediated endocytosis; 3) dependency on 
cargo-specific small GTPases, such as Arf-6 for the internalization of major 
histocompatibility complex I (MHCI) [17], RhoA for uptake of interleukin-2 receptor 
b (IL-2Rβ) [18] and, finally, Cdc-42 and GRAF-1, which regulate the endocytosis of 
fluid-phase markers through the CLIC/GEEC pathway [19].  
Some receptors can be internalized through both CME and NCE routes with 
different signaling outcomes. The choice of internalization pathway is one of the 
many mechanisms used by endocytosis to control signaling output. 
 
1.1.2 Endocytosis regulates cell signaling at different levels 
Regulation of cell signaling through endocytosis can occur at different stages of 
the internalization process: before receptor entry at the PM, at the cell entry route 
selection step, and after endosome formation (Figure 2). 
 At the PM, several mechanisms are used by endocytosis to control receptor 
signaling (Figure 2A). The major mechanism responsible for the negative 
regulation of cell surface signals is ligand-induced internalization of signaling 
receptors: continuous ligand stimulation, including those ligands activating tyrosine 
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kinase receptors (RTKs) and GPCR, induces receptor internalization and 
degradation, thereby reducing the number of receptors from the PM.  
 Another mechanism used by endocytosis for signaling control is the 
recruitment and activation, exclusively at the PM, of specific molecular 
transducers. This approach is used during the internalization of RTKs, such as 
EGFR, and GPCRs (Figure 2A). In the case of EGFR, ligand binding induces 
receptor autophosphorylation that, in the presence of phosphatidylinositol 4,5-
bisphosphate (PIP2) at the PM, leads to either activation of phosphoinositide 3-
kinase (PI3K) or phospholipase Cγ (PLCγ). The activation of these two signaling 
pathways is abrogated in the endosomes by constitutive lack of accessible PIP2 in 
these intracellular compartments [20] (Figure 2A,a). GPCR-mediated signaling via 
PLC starts at the PM where trimeric G proteins reside and where G proteins can 
initiate and mediate signaling, due to the prevalent, if not exclusive, localization of 
PLC substrate, PIP2, at the PM [21] (Figure 2A,b). 
  PIP2 controls also the duration of signals coming from the PM by directly 
regulating the maturation of CCPs [22]. Indeed, in the case of RTKs and GPCRs 
internalization, cargo accumulation in CCPs was shown to be a highly regulated 
process that directly impacts on PM signaling [23].  
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Figure 2 | Endocytosis regulates signaling at different levels.  
A) Endocytosis controls signaling at the PM. B) Different routes regulate different 
biological output. C) Endocytosis can sustain signaling through the endosomes 
[adapted from [4]] (see text for details). 
 
 
 At the PM, endocytosis can also regulate ligand accessibility. One good 
example of this kind of regulation is the Notch receptor system. Notch receptors 
bind ligands of the DSL family (Delta, Serrate and Lag2), which are 
transmembrane proteins. After binding, two proteolitic cleavages occur in the 
Notch-presenting cell, referred as signal-receiving cell. These cleavages release 
the intracellular domain of Notch (NICD), allowing its translocation to the nucleus 
where it promotes the transcription of target genes. Endocytosis seems to be 
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necessary to activate Notch signaling both in signal-receiving and in signal-
sending cells (reviewed in [24, 25]). In the signal-receiving cell, Notch endocytosis 
is essential for a second cleavage that occurs in the endosomes [26]. In the signal-
sending cell, DSL internalization produces a mechanical pulling force that induces 
a conformational change in Notch and leads to Notch internalization and activation 
in the single-receiving cell [27]. Recent evidence in Drosophila melanogaster, 
shows that Delta endocytosis and recycling is essential to achieve high ligand 
concentration at the PM, necessary to activate a robust Notch signaling response 
[28] (Figure 2A,c).  
 At the internalization step, many signaling receptors can select the 
preferred cell entry route. EGFR, transforming growth factor-β receptor (TGFβR), 
Notch and Wnt receptors are some of the receptors that can be internalized either 
through CME or NCE. Of note, internalization of a receptor through different 
endocytic routes results in different final biological outputs (Figure 2B). For 
example, internalization of TGFβR through CME leads to downstream signaling 
(phosphorylation and activation of Smad2 and Smad3 proteins) and recycling of 
the receptors back to the PM (Figure 2B). However, if TGFβR is internalized via 
NCE, the recptor is preferentially targeted for ubiquitination and degradation, a 
process that involves the recruitment of Smad7 and the E3 ligase SMURF [29] 
(Figure 2B,e). 
 While in the case of TGFβR it is not clear the mechanism that regulates the 
entry through a specific endocytic pathway, in the case of EGFR, the choice of 
internalization pathway depends on the dose of ligand and the ubiquitination state 
of the receptor [13, 30, 31] (Figure 2B, d).  
At low EGF dose, EGFR enters the cell via CME, which leads to recycling 
and sustained signaling in the presence of high EGF concentration, the receptor 
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gets heavily ubiquitinated and is preferentially committed to NCE and targeted for 
degradation, thus leading to signal extinction [13, 30, 31]. 
 The last stage of signaling control occurs at the endosomes. Internalized 
cargo proteins are trafficked to intracellular compartments, called early 
endosomes, from which they can be either routed to lysosomes, where they will be 
degraded, or recycled back to the PM, where they can continue their signaling 
activities. Both processes depend on the action of proteins belonging to the Rab 
small GTPase family; in particular, Rab11 guides the cargoes back to PM while 
Rab7 regulates the sorting to lysosomes and degradation (reviewed in [32]).  
Besides this role in regulating protein trafficking, growing evidence suggests that 
early endosomes function as signaling platforms that can regulate duration, 
amplitude and specificity of the downstream signals (reviewed in [2, 4, 33]) (Figure 
2C).  
 Endosomes can influence signaling by sustaining signals coming from the 
PM. Many RTKs remain bound to their ligands along the endocytic route and thus 
active in the endosomal compartments. In the case of EGFR, it has been shown 
that almost the entire ERK-MAPK activation cascade can be detected in the 
endosome [34, 35]. This could be explained by the presence of scaffold proteins, 
such as P18, P14, that anchor MAPK and ERK proteins to the endosomal 
membrane, facilitating their activation [36, 37] (Figure 2C, f). 
 Canonical GPCR signaling was also recently found to continue in the 
endosomal compartment; indeed, it has been demonstrated that the β2-
adrenoreceptor, a prototypical GPCR, can signal both at PM and in the early 
endosomes contributing to the overall cyclic AMP cellular response within several 
minutes after internalization [38].  
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 Endosomes can also support signaling by allowing the assembly of specific 
signaling complexes. One example of this mechanism occurs with TGFβ signaling. 
Onece internalized, TGFβ receptors are routed to endosomes where scaffold 
FYVE-containing protein SARA (Smad anchor for receptor activation) can recruit 
Smad2 to be phosphorylated by TGFβ receptors. This initiates the TGF signaling 
cascade that continues with the formation of Smad2-Smad4 complex and its 
translocation to the nucleus, where activation of the transcription of target genes 
occurs [39, 40] (Figure 2C,g). 
Finally, endosomes are able to regulate the spatial restriction of signals to 
prevent its uniform distribution throughout the cell. Indeed, early endosomes can 
redirect signaling molecules to specialized areas of the PM. Spatial restriction of 
the signals is necessary for the execution of a number of polarized functions, 
including directed cell migration and epithelial-cell polarization [41].  
During chemotactic migration, cells must orient themselves in the right 
direction and their intracellular machinery must be coordinated in order to generate 
propulsive forces [42, 43]. In mammalian cells, motogenic stimuli, such as 
hepatocyte growth factor (HGF), activate clathrin- and Rab5-mediated endocytosis 
of Rac proteins (small GTPases that relay signals from cell surface to actin 
cytoskeleton). Rac activation occurs on early endosomes, where the RacGEF 
Tiam1 is also recruited. This leads to recycling of Rac to specific regions of the PM 
where actin-based migratory protrusions are formed [44] (Figure 3).  
The spatial regulation of the signals is also important to regulate the 
epithelial cell polarity and this is achieved through the trafficking of adhesion 
molecules, such as E-cadherin. E-cadherin, the prototypical epithelial cadherin, is 
localized at the lateral surface of epithelial cells and represents the major 
component of the cell-cell adherent junctions (AJs) [45].  
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 E-cadherin can be internalized through CME and NCE and, thus, it can be 
recycled back to cell surface or committed to degradation (reviewed in [46]). One 
possibility is that the decision to recycle or degrade E-cadherin is executed by the 
endosome-retention machinery. Indeed, it has been shown that EGF-induced E-
cadherin internalization into early endosomes containing the sorting nixing SNX1 
retrieves E-cadherin from degradation while promoting its efficient recycling, and 
the re-establishment of epithelial adhesion [47] (Figure 3).  
 
 
 
 
Figure 3 | Endosome sorting regulates cell signaling  
A) Epithelial cell–cell contacts contain the adherent junctions protein complex of E-
cadherin, p120 catenin (p120), α- catenin and β-catenin. Upon E-cadherin 
internalization, the recruitment of SNX1 in the endosomes leads to recycling. B) 
During growth factor stimulation, some cells form apical protrusions called dorsal 
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ruffles. Endocytic recycling of Rac1 to these dorsal ruffles requires the Rac1 GEF 
Tiam1 on Rab5 endosomes in response to HGF [adapted from [48]] 
 
1.2 Endocytosis and cancer 
The tight and bidirectional connection between endocytosis and cellular signaling 
suggests that alterations of the endocytic programs might have an important role 
in several human pathologies, including cancer.  
 In recent years, intense cancer research originated a wider and deeper 
knowledge of the hallmarks of cancer. These include self-sufficiency in growth 
signals, unlimited replicative potential, resistance to cell death signals, and 
activation of invasion and metastatic programs (reviewed in [49]). Evidence 
suggests that endocytosis is embedded in all these cellular aspects. Indeed, 
endocytosis regulates growth signaling either in a negative fashion, by inducing 
degradation of the growth factor receptors, or in a positive manner by sustaining 
the signals in the endosomes (reviewed in [4]). Furthermore, endocytosis controls 
the spatial restriction of signals needed for directed cell movement adopted by 
metastatic cells, by regulating internalization and recycling of adhesion molecules, 
including cadherins and integrins (reviewed in [41]).  
A subversion of these endocytic functions might play a role in the tumorigenic 
process. Growing evidence suggests that altered vesicular trafficking of growth 
factor receptors and adhesion molecules can have a causative role in tumors. 
Moreover, deregulated expression of various endocytic proteins in human cancers 
has been reported (reviewed in [3, 4, 50]).  
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1.2.1 Starting from the “top”: alterations of PM cargoes – the RTK receptor 
family example  
PM cargoes belonging to the RTK receptor family are frequently mutated in human 
tumors (reviewed in [48]). These mutations can induce changes in the vesicular 
trafficking of cargoes and affect their downstream signaling. RTK receptors, like 
EGFR and Met, sustain proliferative signals in the cell. The major mechanism that 
the cell adopts to restrict prolonged signals deriving from RTK receptors is their 
internalization, ubiquitination and consequent degradation. However, mutations in 
RTKs either increase the kinase activity of the receptors or affect the ability of the 
receptors to be properly ubiquitinated and downregulated (reviewed in [50]). The 
final outcome is, thus, sustained signaling that cannot be attenuated, which 
unbalances cellular homeostasis. 
The EGFR is involved in the transmission of cell differentiation, proliferation 
and survival signals. Somatically acquired mutations in the tyrosine kinase (TK) 
domain of EGFR have been found in non-small-cell lung cancer (NSCLC) patients 
[51]. These mutations increase the kinase activity of the receptor [51, 52] and 
enhance selective transduction of survival signals [51]. EGFR TK mutations are 
found in 10-30% of NSCLC patients and are predictive of significant clinical 
response to the kinase inhibitor gefitinib [51, 52]. Of note, these EGFR mutants 
present in NSCLC are constitutively internalized and are continuously trafficked to 
recycling endosomes, which provides direct evidence of a causative role of 
aberrant trafficking of EGFR in EGFR-mediated oncogenesis [53]. 
Another oncogenic EGFR mutant, named EGFRvIII has been found in 
glioblastoma [54]. This mutant is characterized by an in-frame deletion in its 
extracellular domain and by its incapacity to bind ligands. This mutant form of 
EGFR transforms fibroblast and enhances tumorigenic potential of cancer cells 
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both in vitro and in vivo ([55, 56]. Moreover, EGFRvIII is inefficiently degraded: 
although it can still be internalized, EGFRvIII is recycled back to PM rather than 
being delivered to lysosomes [57]. 
Met, the receptor for HGF is implicated in growth, survival and 
dissemination of various human cancers (reviewed in [58]). Mutations in the kinase 
domain of Met were originally found in human papillary renal carcinoma. These 
mutants exhibit constitutive kinase activity and promote tumorigenesis in vitro and 
in vivo [59, 60]. Recently, it was shown that these mutants are tumorigenic not 
only because they are more active but also because they are continuously 
internalized/recycled and cannot be degraded, which leads to increased Met 
signaling in the endosomes [61].  In this study, the authors show that blocking of 
endocytosis in vivo is able to inhibit the tumorigenic potential of Met mutants, and, 
thus, provide strong supporting evidence for a link between changes in receptor 
endocytosis and tumorigenesis [61].  
One important regulator of RTKs signaling is the E3 ubiquitin ligase Cbl 
(Casitas B-lineage lymphoma) (reviewed in [62]). Indeed, Cbl acts by 
ubiquitinating RTKs, which induces receptor internalization and targets it for 
degradation. The oncogenic forms of Cbl described in the literature are 
characterized by loss of the E3 ligase activity. This leads to impaired degradation 
of RTKs and sustained signaling. Recent studies have found Cbl mutations in 
acute myeloid leukemia (AML) that cause impaired internalization and degradation 
of the Flt3 receptor, a RTK known to regulate hematopoietic progenitor cell 
homeostasis. Of note, Cbl mutants lead to an increased activity of Flt3 and 
downstream signaling of PI3K and STAT pathways [63, 64]. All these observations 
point toward a new mechanism of altered RTKs signaling in human cancers.  
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1.2.2 Moving toward the “inside machine”: alterations of endocytic proteins 
A wide range of endocytic proteins shows altered expression in human cancers 
(reviewed in [3, 50]). A high number of such alterations has been found in recent 
years, but whether there is a causal link between aberrant regulation of 
endocytosis, resulting from the altered expression of such proteins, and 
tumorigenesis remains to be determined. 
 In this section, I will give an overview of what is known about deregulated 
expression of Huntingtin-interacting protein 1 (Hip1), Rab25, Numb, and hypoxia-
induced factor α (HIFα), for which altered expression has been implicated in 
tumorigenesis.  
Hip1 is a cofactor protein involved in CME [65]. Hip1 overexpression has 
been observed in various tumors [66-68]. Even though the genetic liaison 
underlying the changes in Hip expression levels in tumors is not yet known, there 
is biological evidence that deregulation of Hip expression might be causal for 
cancer. Indeed, in prostate cancer, Hip1 protein overexpression promotes survival 
of cancer cells and correlates with prostate cancer progression and metastasis 
[69]. Of note, Hip1 overexpression is able to transform NIH/3T3 fibroblast cells and 
its tumorigenic potential is linked to a deregulation of receptor trafficking, such as 
EGFR. Moreover, EGFR expression is elevated in tumors showing upregulation of 
Hip1 [66-68].  
Rab25 is another prominent example of an endocytic protein whose 
expression is altered in tumors. Rab25 belongs to the Rab11 subfamily of small 
GTPases that regulate the recycling of internalized cargoes back to the PM [32]. 
Elevated expression of Rab25 is found in ovarian and breast cancer and it is 
associated with decreased disease-free survival or overall survival, respectively 
[70]. Forced overexpression of Rab25 increases tumorigenesis in vitro and in vivo 
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of ovarian and breast cancer cells [70]. Rab25 has been reported to directly 
interact with α5β1 integrin promoting its relocalization at the pseudopodial tips at 
the cell front, thus increasing the ability of tumor cells to invade the ECM and form 
metastasis [71, 72]. The overexpression of Rab25 results from gene amplification, 
which provides a more solid genetic basis to propose a causal role in 
tumorigenesis [70].  
In some tumors, downregulation of endocytic proteins is also observed. This 
is the case of the protein Numb. Numb is a cell fate determinant, which controls 
cell fate by both asymmetrical partitioning itself and by antagonizing Notch activity 
[73]. In mammalian cells, Numb works also as an endocytic protein since it binds 
the major components of the CCPs (such as AP2) and co-traffics with internalizing 
receptors [74]. Numb protein expression is severely decreased in breast and lung 
tumors due to protein degradation and this alteration correlates with increased 
Notch activity [75, 76]. Moreover, Numb regulates p53 levels by forming a 
tricomplex with p53 and Hdm2 that results in the inhibition of the p53 
ubiquitination. As a result, Numb-negative breast tumors show decreased p53 
levels [77]. The genetic alterations underlying Numb deregulated expression in 
tumors are not yet known. However, it is clear that perturbation of Numb 
expression has a causative role in cancer, which provides an additional link 
between altered expression of endocytic proteins and tumorigenesis.  
HIF1α is a transcription factor involved in the cellular response to hypoxia. 
Indeed, in the absence of oxygen HIFα is stabilized and activates the expression 
of some hypoxia-response genes, such as vascular endothelial growth factor 
(reviwed in [78]). It has been shown that HIF1α in renal carcinoma cells inhibits the 
transcription of RABAPTIN-5 gene, a critical Rab5 effector [79], which impairs 
Rab5-mediated early endosome fusion and delays the endocytic pathway. As a 
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consequence, the resident time of activated EGFR in endosomes is prolonged and 
signaling leading to cell proliferation and survival is sustained [79]. In agreement 
with this mechanism, tumor hypoxia and HIF1α overexpression generally correlate 
with an aggressive phenotype and poor patient prognosis [79, 80]. Importantly, 
primary kidney and breast tumors with strong hypoxic signatures show significantly 
lower expression of rabaptin-5 RNA and protein [79]. 
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2 Epsin proteins 
Epn3 belongs to the epsin family of endocytic adaptor proteins, which is involved 
in important physiological processes, first and foremost, the coordination of 
endocytosis and signaling. While the other members of the family have been well 
characterized as endocytic adaptors, the exact role of Epn3 in endocytic 
processes is still unknown. Preliminary results from our lab argue for the 
involvement of Epn3 in breast cancer, since the EPN3 gene was identified in a 
signature associated with aggressive breast cancer. These observations prompted 
us to investigate the role of Epn3 in physiology and cancer. In this chapter, I will 
provide an overview of the current knowledge on epsin proteins with a particular 
focus on Epn3 and its biological functions. 
 
2.1  Overview of the epsin protein family  
In mammals, the epsin family is composed of 3 members, named epsin1 
(Epn1), epsin2 (Epn2) and Epn3.  
The first family member to be identified was the rat epsin1 due to its ability 
to bind the accessory endocytic protein Eps15 (indeed, epsin stands for Eps15 
interacting protein1) [81]. In addition to Eps15, Epn1 was found also to bind the 
clathrin adaptor protein AP2 and to colocalize with clathrin coats [81]. In a different 
study, Epn1 was isolated as binding partner of intersectin [82], another endocytic 
factor, and POB1, a component of RalGTPase network [83]. The sequence 
analysis of Epn1 revealed that it is closely related to the Xenopus mitotic 
phosphoprotein MP90 [81].  
Soon after, the second member of the family, Epn2, was identified. Epn2 
shows a high degree of sequence homology to Epn1 and a similar cellular 
localization and expression pattern [84]. Both Epn1 and Epn2 are ubiquitously 
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expressed in all body tissues, although they are enriched in the brain. The two 
proteins show a general cytoplasmic localization in the cell with a pronounced 
accumulation in puncta on the PM [81, 84]. 
The third member of the family, Epn3, was identified as an extracellular 
matrix-induced protein in human keratinocytes. Due to the high sequence 
homology between Epn3 and the two other members of the epsin family, the 
protein was classified as belonging to the epsin family and named Epn3 [85]. 
Nevertheless, Epn3 is distinct from the other epsin proteins, since it has a different 
expression profile in normal tissues. Indeed, Epn3 is not expressed or is 
expressed at low levels in physiological conditions and in normal tissues, apart 
from migrating keratinocytes [85]. However, high expression of Epn3 was found in 
gastric parietal cells and in some cases of gastric cancer [86].  
In vertebrates, another epsin-like protein, also known as epsinR or Epn4, 
displays partial sequence homology with the other epsins, mostly in the N-terminal 
domain (see below) but it possesses different features. Indeed, epsinR is localized 
at the endosome membrane and it is mainly involved in the formation of clathrin 
coated vesicles from the Golgi network and in retrograde transport [87, 88].  
Epsin proteins are evolutionary well conserved with homologues in the 
lower species. Saccharomyces cerevisiae contains at least two epsin paralogs, 
Ent1 and Ent2, while one epsin orthologue, liquid facets (LqF), is present in 
Drosophila. A Xenopus epsin was identified as mitotic phosphoprotein in oocytes 
(MP90) (reviewed in [89]). 
 
2.1.1  Structure and domain organization of epsins 
All members of the epsin family share a common domain organization (Figure 4).  
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At the N-terminus, epsins contain a highly conserved domain of about 150 
amino acids known as the Epsin N-Terminal homology (ENTH) domain. This 
domain has been proposed to represent a separately folded protein module due to 
its structural characteristics [90]. The crystal structure of mammalian ENTH 
domain revealed a superhelical fold comprising seven α helices [91, 92].   
The ENTH domain binds PIP2, which is enriched in endocytic sites within 
the PM. The binding of ENTH to PIP2 contributes to membrane deformation 
occurring at the initial steps of CCP formation [93, 94]. Furthermore, this domain is 
also able to bind to the promyelocytic leukemia zinc finger transcriptional factor 
(PLZF), thus suggesting a possible role of epsin proteins in transcriptional 
regulation [91]. Consistent with this, epsin proteins have been shown to shuttle 
between nucleus and cytoplasm [91, 95]. Nevertheless, the exact role of this 
interaction is not clear yet.  
 
 
Figure 4 | Domain architecture of human epsin family members.  
Different protein domain and their interactors (on the top) are indicated. For a 
detailed description of each domain see text. [adapted from [94]]. 
 
 
Several ubiquitin-interacting motifs (UIMs) are located adjacent to the 
ENTH domain. UIMs are responsible for the monoubiquitination of epsins as well 
as the recognition of ubiquitinated cargos [13, 96, 97].  
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The central part of epsins includes the presence of multiple DPW (Asp-Pro-
Trp) motifs through which epsins bind AP2 complex [81], flanked by clathrin 
binding consensus sequences [98]. The number of these motifs and the affinity for 
these two endocytic components can vary among epsin members: indeed, Epn3 
shows a low affinity to the clathrin binding sequence while the other members 
display a higher affinity [85, 86].  
The C-terminus of the proteins comprises NPF (Asn-Pro-Phe) repeats that 
are required for the binding to EH-containing proteins, including Eps15, POB1 and 
intersectin [81-83, 99, 100]  
 
2.1.2  Biological functions of epsins 
Epsin proteins fulfill different roles in the endocytic process by acting as adaptor 
proteins that link surface receptors to the major components of endocytic 
machinery, i.e. AP2, clathrin and Eps15.   
Many studies have demonstrated a clear role for Epn1 and Epn2 in the 
internalization process of various cargoes, while the exact function of Epn3 in 
endocytosis and/or signaling is still missing. Therefore, the biological functions 
described below are referred only to the first two members of the family.  
Genetic studies conducted in Drosophila melanogaster demonstrated that 
the epsin parologue, liquid facet (LqF), is essential for the endocytosis of the 
Notch ligands DSL in the signal-sending cell [101, 102]. Furthermore, epsin-
dependent endocytosis of DSL produces a mechanical pulling force that drives 
Notch conformational change necessary for Notch internalization and activation in 
the single-receiving cell [27]. Since endocytosis of both DSL ligands and Notch is 
essential to activate Notch-dependent signaling, epsin contributes to Notch 
pathway activation.  
 
 
33 
A detailed study of double Epn1/Epn2 knock-out (KO) mice revealed that 
these proteins are essential for vitality, since embryos died during gestation, and 
that Epn1 and Epn2 are redundant, since single KO pups were viable [103]. 
Interestingly, development defects observed in double KO embryos recapitulate 
those produced by inhibition of Notch signaling [103]. 
In mammals, it has been widely demonstrated that Epn1, together with 
Eps15, plays a role in both CME and in NCE of EGFR. In the latter case, this is 
mediated by the ability of Epn1 to bind ubiquitinated EGFR via UIM [13]. Besides 
EGFR, Epn1 and Epn2 also bind the ubiquitinated form of vascular endothelial 
growth factor receptor (VEGRF), and, by doing so, allow its internalization and 
degradation [104]. As a consequence, loss of Epn1 and Epn2 in endothelial tissue 
results in excessive VEGFR signaling that leads to disorganized vasculature, leaky 
tumor angiogenesis and tumor growth retardation [104]. 
Complementary to their endocytic role, epsins are involved in many other 
cellular processes. For instance, epsin proteins are able to regulate small 
GTPases and, consequently, actin-based motility and polarity.  
In yeast, the ENTH domain interacts with Cdc42 GTPase-activating proteins 
(Cdc42 GAPs) regulating polarized cell growth. This interaction is necessary to 
sustain cell viability [105].  
In mammals, epsin proteins exert important functions in the regulation of 
Rho GTPase signaling. Specifically, epsin interacts through its ENTH domain with 
Ral-binding protein 1 (RalBP1) and this interaction leads to cell migration in 
fibrosarcoma cell lines [106].  
Finally, a number of studies conducted in mammalian cells, revealed that 
epsin proteins are subjected to Cdk1-dependent phosphorylation that renders 
them incompetent for the binding to AP2 and Eps15 and, thus, unable to play their 
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endocytic role [107, 108]. Furthermore, epsin proteins regulate mitotic membrane 
morphology and spindle orientation during mitosis through its ability to induce 
membrane curvature [109]. Therefore, the endocytic function of epsins and its role 
in mitosis are mutually exclusive and tightly regulated.  
 
2.2  The case of Epn3: what makes the difference 
The protein Epn3 shows the same domain architecture and a high degree of 
sequence identity when compared to the other two members of the family.  
Indeed, Epn3 contains the highly conserved ENTH domain with more than 90% 
homology. Epn3 also contains multiple DPW and NPF motifs to bind AP2 and 
Eps15. Differently from Epn1 and Epn2, Epn3 exhibits a low affinity clathrin 
binding [85] (Spradling et al JBC 2001).  
This similarity of sequence and domain organization suggests that Epn3 
could behave analogously to the other epsins. Indeed, like the other members, 
Epn3 shows a cytoplasmic localization with a pronounced accumulation in 
perinuclear region. Furthermore, like Epn1 and Epn2, Epn3 co-localizes with 
clathrin coated-structures and is able to shuttle between cytoplasm and nucleus 
[85, 86]. Finally, together with the other epsins, Epn3 has been shown to be 
involved in membrane fission and clathrin-coated vesicle formation [110]. 
The characteristic that makes Epn3 divergent from the other epsins is its 
different tissue expression pattern. Unlike Epn1 and Epn2, which are ubiquitously 
expressed, Epn3 is prevalently expressed in gastric parietal cells [86] and in 
wounded or pathological epithelial tissues exhibiting altered cell-extracellular 
matrix interaction [85]. In particular, Epn3 expression was found to be upregulated 
in migrating keratinocytes in cutaneous wounds, but not in differentiating cells [85].  
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In gastric cells, Epn3 high expression levels are found in the apical caniculi 
where it co-localizes with clathrin. These cells are specialized in the control of the 
stomach lumen acidification via exo-endocytosis of vesicles containing H/K 
ATPase [86].  
All these data suggest a putative role of Epn3 in the endocytic process. 
However, the exact function of this atypical epsin in endocytosis, signaling and/or 
cell migration is still unknown.   
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3 Breast cancer 
The project presented here is based on the preliminary results derived from a 
gene-expression analysis of a small cohort human breast tumor samples showing 
the association between expression of the endocytic protein Epn3 and poor 
prognosis in breast cancer patients. These preliminary data strongly argued for a 
role of Epn3 as a breast cancer marker with potential to be used in the clinical 
management of the disease. In light of this data, we decided to investigate the 
involvement of Epn3 in breast cancer initiation.  
Breast cancer is the most commonly diagnosed cancer and the main cause 
of cancer-related deaths in women worldwide. Despite the fact that state-of-the-art 
diagnostic and therapeutic tools allow to treat breast cancer patients at the very 
early stage of disease, disease recurrence and metastasis are responsible for the 
most part of breast cancer-related deaths. This situation is mainly due to our 
incapacity to predict breast cancer evolution. Breast cancer is a complex and 
heterogeneous disease, made up of distinct clinical, morphological and molecular 
entities [111] and our understanding of the mechanisms underlying its progression 
is still limited. The molecular profile of breast cancer should help to understand 
how tumors can differ among patients and to predict the clinical outcome and the 
response to specific therapy. A major need in the clinical management of breast 
cancer patients is, therefore, the identification and validation of molecular 
signatures or individual genes as prognostic markers able to predict the risk of 
disease recurrence and that can be used to better stratify the patients and develop 
more rationale therapies. Epn3 might be one of such markers. 
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3.1 Histological and molecular classification of breast cancer 
Pathologists, on the basis of their microscopic observations, have classified breast 
cancer in non-invasive or invasive types [112, 113]. Non-invasive breast cancer, 
also referred as in situ, is characterized by the presence of cancer cells restricted 
to the basement membrane; the most common type of non-invasive breast cancer 
is the Ductal Carcinoma in situ (DCIS) [112]. On the other hand, the invasive 
breast cancer occurs when cancer cells infiltrate the surrounding tissues. Invasive 
tumors show a higher risk to form metastasis. The invasive ductal carcinoma (IDC) 
represents the most frequent type, comprising the 70-80% of all the breast cancer 
cases [113].  
Although useful, the histological classification of breast cancer does not 
take into account the molecular features of the disease. To investigate the 
molecular differences between breast tumors, researchers have relied on gene 
expression microarrays. Such approach consents the simultaneous expression 
analysis of thousands of genes in breast tumors, and thus allows creating 
molecular profiles of the analyzed breast cancers. 
Perou’s group was the first to provide a molecular classification of breast 
cancer, using cDNA microarray of 38 breast cancer cases [111]. An unsupervised 
analysis was used for grouping several breast tumors according to their biological 
characteristics regardless their clinical and prognostic variables.  The classification 
divides breast cancer into 4 main groups, named Luminal-A, Luminal-B, HER2 and 
Basal-like. The identification of these molecular classes was validated by several 
subsequent studies [114-116]. After this initial classification, new molecular 
subtypes have been identified, such as claudin-low [117] and normal-like [118]. 
 The main four molecular breast cancer subtypes are briefly described 
below (Figure 5). 
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Luminal A breast carcinoma represents 50-60% of all breast cancer cases. 
This type of tumor is characterized by high expression levels of estrogen receptor 
(ER) and progesterone receptor (PgR), absence of HER2 expression, low 
proliferation rate and low grade. Patients with this type of breast carcinoma have a 
good prognosis [114].  
Luminal B type makes up 10-20% of all breast cancers. Luminal B 
carcinoma has a more aggressive behavior, higher histological grade, higher 
proliferative index and worse prognosis than Luminal A [111]. Luminal A and B 
tumors express ER, but due to their differences in prognosis, there is a strong 
need to find other biomarkers able to distinguish between these two subtypes. 
The HER2 subtype represents 15-20% of all breast cancer cases and is 
characterized by high expression of HER2 and other genes associated with HER2 
amplicon located on chromosome 17. These tumors are highly proliferative, they 
have high histological grade and have p53 mutations. From the clinical point of 
view, HER2 subtype is characterized by a poor prognosis [116].  
Basal-like breast carcinoma comprises 10-20% of breast cancer cases and 
is more frequent in a premenopausal age [119]. One of the most relevant features 
of this tumor subtype is the absence of expression of all the three key receptors in 
breast cancer: ER, PgR and HER2. Therefore, these tumors are also called “triple 
negative”. The basal-like subtype is characterized by high rate of p53 mutations 
and occurs commonly in BRCA1 germline mutations carriers. All these 
characteristics result in the poor prognosis of basal-like carcinoma patients. 
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Figure 5 | Molecular class of breast cancer with clinico-pathological features.  
HER2 status, estrogen receptor (ER) and proliferation index (Ki67) are 
represented for each molecular subtype. They determined by 
immunohistochemical (IHC) analysis. [adapted from [116]] 
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3.2 Clinical management of breast cancer patients 
Despite the fact that in the last decade the technological development allowed 
advances in diagnosing and treating breast cancer patients, breast cancer is still 
the leading cause of cancer-related women deaths [120]. Indeed, our ability to 
treat advanced and metastatic breast cancers is still limited and this results in a 
high death rate for breast cancer at these stages.  
 Current routine clinical management of breast cancer patients involves the 
evaluation of clinico-pathological and biological markers that are used to 
determine prognosis and response to therapies. The classical markers include 
clinical and histological factors, such as tumor size, axillary lymph node status 
[121], tumor grade [122], but also biological factors, such as proliferative index 
[123], HER2 [124] and hormone receptors status [125]. However, disease 
recurrence in breast cancer patients is high and clinicians do not have the 
necessary tools to predict it. Indeed, optical predictors of metastases have yet to 
be identified. 
 Targeted therapies have been developed during the last years, including 
endocrine therapy (i.e.tamoxifen) to treat hormone receptors positive patients, and 
anti-HER2 therapy (i.e.trastuzumab) that is specific for HER2 positive patients. For 
instance, trastuzumab is the first-line treatment for HER2-positive metastatic 
breast cancer patients, in combination with adjuvant chemotherapy agents [126]. 
Nevertheless, only 30% of the patients harboring HER2 overexpression respond to 
this treatment regimen, while approximately 70% of patients may have resistance 
to trastuzumab (reviewed in [127]).  
 Thus, the clinical management of breast cancer patients remains 
complicated, mainly because we still do not understand completely the 
mechanisms of tumor progression. We need a deeper knowledge of tumor biology 
 
 
41 
and microenvironment to be able to provide patients with better and individualized 
care. An individualized approach to breast management has the potential to offer 
clear clinical benefits as well as the ability to bring more tailored and cost-effective 
strategies to breast cancer patients. Currently, the more promising approach to 
provide a real improvement in the clinical management of breast cancer patients 
relies on the identification of specific biomarkers to predict disease progression.  
 
3.3 Predictive and prognostic gene signatures in breast cancer 
The application of high-throughput technologies, such as microarrays, to gene 
expression analysis of tumors has allowed the generation of prognostic and 
predictive gene signatures that are useful to predict the outcome and the response 
to therapy of breast cancer patients (reviewed in [128]).  
The first prognostic breast cancer gene signature was identified in the work 
of Van’t Veer et al in 2002 [129]. In this study, researchers used cDNA microarray 
analysis of primary breast tumors and identified a list of 70 genes able to 
discrimate between good and bad prognosis. This “poor prognosis” signature was 
found to be strongly predictive of disease outcome, as defined by the presence of 
distant metastasis within 5 years  [129, 130]. A subsequent study by Minn and 
colleagues screened for genes associated with the ability of breast cancer cells to 
form metastases [131]. Through the analysis of gene expression data, a signature 
associated with the formation of breast cancer lung metastases and poor outcome 
was identified [131]. During the last years, several prognostic and predictive gene 
signatures have been generated but only few of them are really used to stratify 
breast cancer patients.  
One of those signatures is represented by the Mammaprint test. 
Mammaprint was the first commercialized microarray-based multigene assay for 
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breast cancer (Agendia). This test comprises 70 genes and was generated from 
node-negative breast cancer patients who did not receive any adjuvant therapy 
[132].  The different expression of the 70 genes, which is evaluated by the assay, 
allows the stratification of breast cancer patients into good or poor prognosis 
groups.  The Breast Cancer International Group has launched a clinical trial, 
named MINDACT (Microarray In Node negative Disease may Avoid 
ChemoTherapy) to determine whether this molecular test can identify low-risk 
patients who can be spared from cytotoxic therapy [133]. 
An alternative approach to Mammaprint assay is the Oncotype DX assay. 
This assay measures the expression of 21 genes in formalin-fixed paraffin-
embedded tumor samples through RT-PCR. Oncotype DX assay has shown to 
predict the risk of recurrence in node-negative, ER positive breast cancer patients 
who had received treatment with tamoxifen [134].  
Although the results of the introduction of these technologies in the clinical 
management of breast cancer patients are quite promising, it is still not clear if 
these gene expression-profiling techniques will be capable of replacing the 
traditional methods based on histopathological assessments. An alternative 
approach could be the development of signatures comprising a limited number of 
genes with validated antibodies suitable for IHC detection of their respective 
proteins. This approach, together with the development of more sophisticated and 
automated imaging methods, would hypothetically provide uniform, objective and 
more comparable information for routine clinical practice.  
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MATERIALS AND METHODS 
1 Tissue microarray (TMA) studies 
1.1 Patient selection and study design.  
Case-control study group: we established a case-control study on a large series of 
breast cancer patients (n = 349) who had undergone surgery at the European 
Institute of Oncology (IEO) in Milan for the removal of primary breast cancer 
between 1994 and 1997. Disease recurrence (any relapse and distant relapse) 
was within 18 years (median 9.2 years and 10.6 years respectively). For some 
patients not all information was available. (See Table 1 for further details on 
patient characteristics) 
Validation study group: this group included 916 breast cancer patients who 
underwent surgery at IEO for the removal of primary breast cancer between 1997 
and 2000. For some patients not all information was available. (See Table 2 for 
further details on patient characteristics). 
Written informed consent for research use of biological samples was obtained 
from all patients, and the research project was approved by IEO’s Institutional 
Ethical Committee. 
 
1.2 Analysis of Epn3 expression in breast cancers by 
immunohistochemistry on TMA  
Tissue sample preparation, IHC and TMA-IHC analyses were performed in 
collaboration with the Molecular Pathology Unit at the IEO, Milan. 
Normal (when available) and tumor areas (diameter 0.6 mm) from each biopsy 
sample, previously identified on haematoxylin-eosin stained sections, were 
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removed from the paraffin donor blocks and deposited on the recipient block using 
a custom-built precision instrument (Tissue Arrayer - Beecher Instruments, Sun 
Prairie, WI 53590, USA). Two-µm sections of the resulting recipient block were 
cut, mounted on glass slides, and used for IHC. 
 TMAs were analyzed for Epn3 protein expression by IHC. TMA sections 
were routinely processed, placed for 30 minutes in 0.25 mM EDTA at 95°C for 
antigen retrieval and incubated for 3 hours with the VI31 anti-Epn3 monoclonal 
antibody (1:30 0000, produced in-house); bound antibody was revealed using the 
EnVision Plus/HRP detection system (DAKO) and diaminobenzidine as a 
chromogenic substrate. TMA sections were finally counterstained with hematoxylin 
and mounted. Positive and negative controls were included in each experiment 
and only clear staining of the tumor cell nuclei was considered positive for Epn3 
expression. A semiquantitative approach was used to generate a score for each 
tissue core, ranging from 0 to 3 according to the signal intensity. Scores 1 (weak), 
2 (moderate) and 3 (strong) were assigned when at least 30% of tumor cells in the 
sample were positive. 
 Tumors showing IHC scores > 1.0 were assigned to the Epn3-HIGH group, 
whereas those with IHC scores ≤ 1.0 were considered as the Epn3-LOW group. 
ER and PgR proteins, measured by IHC on whole tissue sections, were retrieved 
from histopathology reports. The rate of proliferation was measured by 
determining the percentage of nuclei in which labeled antigen Ki-67, a marker of 
cell division, was expressed (MIB1 antibody DAKO, Cytomation). HER2 
expression was measured by IHC on TMAs, processed as previously described, 
using an anti-HER2 polyclonal antibody (1:160, DAKO, Cytomation). HER2 
overexpression was evaluated according to the scoring system recommended by 
the DAKO HercepTest: score 0, no staining or membrane staining in <10% of the 
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tumor cells; score 1, barely perceptible membrane staining in >10% of the tumor 
cells; score 2, weak-to-moderate staining of the entire membrane in >10% of the 
tumor cells; score 3, strong staining of the entire membrane in >10% of the tumor 
cells. Scores of 2 and 3 were considered to represent overexpression. 
1.3 Statistical analysis 
Association between the clinical/pathological features of the tumors and Epn3 
expression was evaluated by the Fisher’s exact test. In the breast cancer 
validation cohort, logistic regression was used to assess the association between 
Epn3 expression and the presence or absence of events (relapse or death) from 
the date of surgery to the date of the event or the date of last follow-up. Follow-up 
was updated to 2012. Kaplan-Meier plots were carried out by means of the 
proportional hazards Cox-model. All P-values were two- sided. A P-value equal to 
or less than 0.05 was considered significant. All statistical analyses were carried 
out using SAS statistical software (SAS Institute, Inc., Cary, NC). 
1.4 FISH analysis 
FISH on breast TMAs and breast cell lines was performed in collaboration with the 
Molecular Pathology Unit at the IEO in Milan. 
 DNA probes were labeled with a fluorescent dye (Cy3-dUTP or Green-
dUTP) that is incorporated into the DNA by nick translation. The following reaction 
mixture was used: 3µl Buffer 10X, 0.6µl dAGC, 0.3µl dUTP/Cy-3, 3µl ß-
mercaptoethanol, 0.3µl DNA polymerase, 6µl DNase (1:700 in H2O), and 5 µg 
DNA in 30 µl final volume. The reaction mix was incubated at 16°C for 2 hours. 
The probe was precipitated using the following reaction mixture: 3µl salmon sperm 
DNA, 10µl Cot-1 DNA, 1/10 volume NaAcetate, 3 volumes of cold 100% ethanol. 
The reaction was then placed at -80°C for 15min (or at - 20°C for 30 min) and then 
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centrifuged at 13000 rpm for 20 min at 4°C. The supernatant was removed and 
the pellet dried and resuspended in 15 µl of hybridization mix (for 15ml: 7.5 ml 
ultrapure formamide, 6 ml dextran solphate 25%, 1.5 ml 20 x SSC). The mixture 
was then incubated with shaking for 10 min at room temperature.  
 To prepare the cells, the cell suspension was centrifuged at 1500 rpm for 
10 min at room temperature. The supernatant was removed and the cell pellet was 
resuspended in 10 ml hypotonic solution (0.075M KCL) and incubated at 37°C for 
18 min. Cells were then fixed in 3:1 methanol:acetic acid. 
For the probe hybridyzation, probes, dissolved in hybridization mix, were placed 
on pretreated slides, and covered with a coverslip and sealed with rubber cement. 
Slides were placed in a Hybrite machine (Vysis) and incubated at 73°C for 3 min 
and then at 37°C overnight. Slides were then washed 3 times in 0.1x SSC for 5 
min each wash, then incubated with DAPI (DAPI in 2 X SSC) for 5 min. 
2 Reagents 
Human recombinant TGFβ1 was from Tebu-bio. TGFβ kinase inhibitor LY2109761 
was purchased from Selleckbio.  
2.1 Antibodies 
For western blot, anti-Epn3 VI31 antibody (epitope: aa residues 464-483, Homo 
sapiens) and anti-Epn1/2 (epitope: aa 249-401, Homo sapiens) were produced in-
house through the Antibody Facility. Anti-vinculin, anti-tubulin and anti-Flag were 
from Sigma. Anti-E-cadherin, anti-N-cadherin and anti-Vimentin were from 
Transduction BD. Anti-Snail, anti-P-Smad2, anti-P-Smad3 were from Cell 
Signaling. For immunofluorescence, anti-E-cadherin was from Transduction BD. 
For E-cadherin internalization assay, anti-Ecadherin (HECD-1) was from Abcam.  
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2.2 Constructs and plasmids 
The pSicoR lentiviral vectors (Addgene), developed by Ventura et al. [135], were 
used for constitutive shRNA expression. Vectors were engineered to express 
shRNA specifically targeting Epn3 expression (shEpn3#1, shEpn3#2) or luciferase 
(shLuc) and mismatch (shMis) as a controls. The pSicoR vector expresses the 
puromycin resistance gene as selection marker.  
 The pBABE retroviral vector was used to generate a construct to 
overexpress Epn3 in mammalian cells. The human Epn3 coding sequence was 
previously cloned downstream the Flag epitope in pBABE vector. The pBABE 
vector expresses the puromycin resistance gene as selection marker.  
 The pLVX-puro lentiviral vector was used to generate a construct to 
overexpress Epn3 in mammalian cells. The human Epn3 coding sequence, 
already present in the lab, was inserted by digestion with the restriction enzymes  
(New England Biolabs) and ligation into the pLVX-puro vector from pCDNA vector 
already present in the lab. pLVX contains a puromycin resistance gene  
 
2.3 RNAi oligos 
For stable Epn3 KD the following shRNA oligo sequences were used: 
shEpn3#1:Fwd-TGCGAGAACCTCTACACCATTTCAAGAGAATGGTGTAGAGG 
TTCTCGCTTTTTTC 
shEpn3#1:Rev-TCGAGAAAAAAGCGAGAACCTCTACACCATTCTCTTGAAAT 
GGTGTAGAGGTTCTCGCA 
shEpn3#2: FWD-TGAGCTAGAAACTGAACGCCTTCAAGAGAGGCGTTCAGTTT 
CTAGCTCTTTTTTC 
shEpn3#2: Rev-TCGAGAAAAAAGAGCTAGAAACTGAACGCCTCTCTTGA 
AGGCGTTCAGTTTCTAGCTCA 
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shOligoMis: Fwd- TGAGCGAACCGATACACTATTTCAAGAGAATAGTGTA 
TCGGTTCGCTCTTTTTTC 
shOligoMis: Rev- TCGAGAAAAAAGAGCGAACCGATACACTATTCTCTTG 
AAATAGTGTATCGGTTCGCTCA 
 
For transient KD of TGFβ receptors the following oligos from Qiagen were used: 
TGFBR1 smart pool: 
GAGAAGAACGUUCGUGGUU 
UGCGAGAACUAUUGUGUUA  
GACCACAGACAAAGUUAUA  
CGAGAUAGGCCGUUUGUAU 
TGFBR2 smart pool: 
CAACAACGGUGCAGUCAAG 
GACGAGAACAUAACACUAG 
GAAAUGACAUCUCGCUGUA 
CCAAUAUCCUCGUGAAGAA 
 
2.4 Q-PCR 
For Q-PCR experiments the Taqman chemistry (Applied Biosystems) was used. In 
the table below, the Taqman assays employed are listed: 
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Gene symbol Assay ID Ref Seq 
EPN3 hs00978957_m1 NM_017957.1 
CDH1 hs00170423_m1 NM_004360.3 
CDH2 hs00169953_m1 NM_001792.3 
VIM hs00185584_m1 NM_003380.3 
TGFB1 Hs00998133_m1 NM_000660.4 
TGFB2 hs00234244_m1 NM_003238.3 
TGFBR1 hs00610320_m1 NM_004612.2 
TGFBR2 hs00234253_m1 NM_003242.5 
18S Hs99999901_s1 X03205.1 
 
3 Cloning techniques 
3.1 Agarose gel electrophoresis 
DNA samples were loaded on 0.8%-2% agarose gels along with DNA markers (1 
kb DNA Ladder, NEB). Gels were made in TAE buffer containing Gel Red 
(Biotium), according to manufacturer’s instructions, and run at 80 V until desired 
separation was achieved. DNA bands were visualized under a UV lamp. 
3.2 Minipreps 
Individual colonies were used to inoculate 2 ml LB (containing the appropriate 
antibiotic) and grown overnight at 37°C. Bacteria were transferred to Eppendorf 
tubes and centrifuged for 5 minutes at 16,000xg using a 5415 R centrifuge. 
Minipreps were performed with the Wizard Plus SV Minipreps Kit (Promega) 
following manufacturer’s instructions. The plasmids were eluted in 50 µl nuclease 
free H2O. 
3.3 Diagnostic DNA restriction 
Between 0.5 and 5 µg DNA were digested for 2 hours at 37°C with 10-20 units of 
restriction enzyme (New England Biolabs). For digestion, the volume was made up 
to 20- 50 µl with the appropriate buffer and distilled H2O. 
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3.4  Large scale plasmid preparation 
Cells containing transfected DNA were expanded into 250 ml cultures overnight. 
Plasmid DNA was isolated from these cells using the Qiagen Maxi-prep kit 
according to manufacturer’s instructions. 
3.5 Transformation of competent cells 
An aliquot of competent cells TOP10 (Invitrogen) were thawed on ice for 
approximately 10 minutes prior to the addition of plasmid DNA. Cells were 
incubated with DNA on ice for 30 minutes and then subjected to a heat shock for 
45 seconds at 42°C. Cells were returned to ice for an additional 5 minutes. Then, 
300 µl of SOC was added and the cells were left at 37°C for a further 60 minutes 
before plating them onto agar plates with the appropriate antibiotic. Two plates for 
each reaction were used, one plated with 100 µl of the transformed bacterial cells 
and the other one with the rest. Plates were incubated overnight at 37°C. 
 
4 Cell culture procedures 
4.1 Cell lines 
All human breast cell lines were from the American Type Culture Collection 
(ATCC). The MDA-MB-361, BT474, MCF7 and SKBR3 cell lines were cultured in 
DMEM medium (from Lonza), supplemented with 10% fetal bovine serum (FBS, 
HyClone) and 4 mM L- glutamine (Euroclone). The HCC1569, HCC1428, ZR7530, 
ZR751 and AU565 cell lines were cultured in RPMI-1640 medium (from Lonza), 
supplemented with 10% FBS and 4 mM L- glutamine. The BT483 cell line was 
cultured in RPMI-1640 medium supplemented with 20% FBS and 0.01 mg/ml 
insulin (Sigma). MDA-MB-175 cell line was cultured in Leibovitz’s L-15 medium 
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(Invitrogen, Life Science Technologies) supplemented with 10% FBS. MDA-MB-
436 cell line was cultured in Leibovitz's L-15 medium supplemented with 10% 
FBS, 10 µg/ml insulin, 16 µg/ml glutathione (from Sigma). The MCF10A cell line 
was cultured in a 1:1 mixture of DMEM and Ham’s F12 medium (Gibco, Life 
Technologies), supplemented with 5% Horse Serum (Invitrogen), 20 ng/ml human 
epidermal growth factor (EGF; Invitrogen), and 50 ng/ml cholera toxin, 10 µg/ml 
insulin and 500 ng/ml hydrocortisone (from Sigma). The UACC-812 cell line was 
cultured in Leibovitz's L-15 medium supplemented with 20% FBS, 2 mM L-
glutamine and 20 ng/ml human EGF. All cells were cultured at 37°C in a 
humidified atmosphere containing 5% CO2. 
4.2 Retroviral and lentiviral infections 
Retroviruses were packaged by transfection of either pBABE, pBABE-Flag-Epn3, 
pBABE-Flag-Epn1 or pBABE-mTwist vectors in phoenix cells. Twenty-four hours 
(24 h) after transfection, the supernatant was discarded and replaced with 5 mL of 
fresh medium concentrated to 5 ml for each 10 cm plate and, 24 h later, the 
supernatant was collected, filtered through a 45 µm filter and added to MCF10A 
cells (40%-50% confluent), which were then incubated at 37°C for 8 h. MCF10A 
cells were passaged 24 h after infection and puromycin (2 µg/ml) was added to the 
culture. 
 Lentiviruses were packaged by transfection of either pSicoR, pSicorR-
shLUC, pSicoR-shEpn3#1, pSicoR-shEpn3#2, pLVX, or pLVX-Epn3 together with 
the helper vectors in 293T cells. After transfection (24 h), the supernatant was 
concentrated to 5 ml for each plate; 24 h later, supernatant was collected, filtered 
through 45 µm filter and added to the cells. Viral supernatant was overlayed on the 
MCF7, BT474 or HCC1569 cells at 40% confluence and incubated at 37°C for 8 h. 
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Cells were passaged 24 h after infection and puromycin (1.5 µg/ml) was added to 
the culture. 
4.3 Transient transfections 
RNAi transfections were performed using Lipofectamine RNAimax reagent from 
Invitrogen, according to manufacturer’s instructions. Cells were subjected to 
double transfection, treated with 8 nM RNAi oligos and analyzed 4 days after 
transfection. The negative control siRNA used was All Stars from Qiagen. 
4.4 mRNA extraction and cDNA synthesis 
mRNA from control and test cell lines was extracted using the RNeasy kit from 
Qiagen, according to the manufacturer’s protocol. 
Single stranded cDNA synthesis was performed using the SuperScriptII reverse 
trancriptase (Invitrogen) following manufacturer’s instructions. Briefly, 1 µg of total 
RNA was mixed with 250 ng of random primers in RNase-free water and then 
incubated at 70°C for 5 min. Following the incubation, 10X reaction buffer, dNTPs 
mix (0.5 mM final concentration), and 1 µl of reverse transcriptase were added to 
the mix (20 µl final volume) and the reaction was incubated at 42°C for 1 hour. 
Finally, the reaction was inactivated by heating at 70°C for 15 min. 
4.5 Immunofluorescence studies 
Cells were plated on glass coverslips. Cells were fixed in 4% paraformaldehyde (in 
Pipes Buffer) for 10 min, washed with PBS and permeabilized in PBS 0.1% Triton 
X-100 for 10 min at room temperature. To prevent non-specific binding of the 
antibodies, cells were incubated with PBS in the presence of 5% BSA for 30 min. 
The coverslips were incubated with primary antibodies diluted in PBS 0.2 % BSA. 
After 1 hour of incubation at room temperature, coverslips were washed 3 times 
with PBS. Cells were then incubated for 30 min at room temperature with the 
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appropriate secondary antibody Cy3 (Amersham), Alexa 488-conjugated 
(Molecular Probes). 
After three washes in PBS, coverslips were mounted in a 90% glycerol solution 
containing diazabicyclo-(2.2.2)octane antifade (Sigma) and examined under a 
wild-field immunofluorescence microscope (Leica). Images were further processed 
with the Adobe Photoshop software (Adobe) or with Image J to merge the images 
of the single channels. 
 
5 Protein procedures 
5.1 Cell lysis 
After washing with PBS 1X, cells were lysed in RIPA directly in the cell culture 
plates using a cell-scraper and clarified by centrifugation at 16,000 xg for 10 min at 
4oC using a 5415 R centrifuge. Protein concentration was measured by the 
Bradford assay (Biorad) following manufacturer’s instructions. 
5.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Gels for resolution of proteins were made from a 30%, 37,5:1 mix of acrylamide: 
bisacrylamide (Sigma). As polymerization catalysts, 10% ammonium persulphate 
(APS) and TEMED were used. 
5.3 Western blot (WB) 
Desired amounts of proteins were loaded onto 1-1.5 mm thick SDS-PAGE gels for 
electrophoresis (Biorad). Proteins were transferred in western transfer tanks 
(Biorad) to nitrocellulose (Schleicher and Schnell) in 1X Western transfer buffer 
(supplemented with 20% methanol) at 30 V overnight or 100 V for 1 hour for small 
gels and at 30 V overnight or 0.8 A for 2 hours for large gels. Ponceau staining 
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was used to determine the efficiency protein transfer onto the filters. Filters were 
blocked for 1 hour (or overnight) in 5% milk in TBS supplemented with 0.1% 
Tween (TBS-T). After blocking, filters were incubated with the primary antibody, 
diluted in TBS-T 5% milk, for 1 hour at room temperature, followed by three 
washes of five minutes each in TBS-T. Filters were then incubated with the 
appropriate horseradish peroxidase-conjugated secondary antibody diluted in 
TBS-T for 30 min. After the incubation with the secondary antibody, the filter was 
washed 3 times in TBS-T (5 minutes each) and the bound secondary antibody was 
revealed using the ECL method (Amersham). 
 
6 Biological assays 
6.1 Soft agar assay 
For soft agar assays, 1% base bottom agar and 0.4% top agarose (GIBCO) 
solutions were prepared. A stock solution of 5% agarose was prepared by 
dissolving 5g of agarose in 100 ml of PBS and aliquots of 30 ml were prepared 
and sterilized by autoclave and store at 4oC.  At the moment of the experiment, the 
stock solution of agarose was dissolved in microwave and then mixed with culture 
medium at the final concentration of 1% and 4 ml were added in each 6-multiwell 
of a plate (bottom agar layer). The bottom agar layer was incubated at 4oC. 
Meanwhile cells were trypsinized and counted and a cellular suspension of 25 000 
cells/ml was prepared.  Top agar layer was prepared by mixing 46ml of culture 
medium and 4 ml of stock agar solution (5%). Then 1 ml of the cellular suspension 
was added to 3ml of top agar solution and the total 4ml of cells and agar were 
plated in 6-multiwell plates and incubated for 3 weeks. After this period, colonies 
were counted at the phase-contrast microscope (magnification 4x).  
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6.2 In vivo xenografts assay 
Six to 8 week-old NOD/SCID IL2R gamma-chain null female mice were injected in 
the inguinal mammary fat pad with 300 000 BT474 and 1 000 000 HCC1569 cells 
 For the preparation of the cells, cells were trypsinized and resuspended in 
sterilized PBS. Cells were centrifuged at 1200 rpm for 5 minutes and cellular pellet 
was resuspended in 10ml of PBS and counted. The desired total number of cells 
was centrifuged again in at 1200 rpm for 5 minutes and cells were in 40 µL of a 
1:1 Matrigel-PBS solution and immediately injected into the inguinal mammary fat 
pad of NOD/SCID IL2R gamma-chain null female mice. Mice were monitored by 
hand-palpation for tumor development. Tumor growth was measured by using a 
vernier caliper and applying the standard formula: tumor volume = (a x b2)/2. Mice 
were sacrificed when tumors reached a dimension of 1.5 – 2 mm3. Tumors were 
explanted and processed for cell extraction.  
6.3 Invasion assay 
Invasion assays Growth Factor Reduced Matrigel invasion chambers placed on 
24-multiwell plates from BD were used. Cells were trypsinized, resuspended in 
culture medium and counted. 40000 cells were resuspended in 500ul of culture 
medium and added to the top chamber of the transwells and incubated at 37°C for 
24 h. After 24h of incubation, transwells were washed with PBS and fixed with 
PFA 4% for 20 minutes. Transwell filters were stained with crystal violet for 20 
minutes and then extensive washes with H2O were performed. Stained 
membranes were used to take photographs of cells and then were dissolved in 
100ul of 10% acetic acid and absorbance at 595 nm was measured at 
spectrophotometer. 
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6.4 Mammosphere-forming assay 
Mammosphere forming assays were performed as described in [136]. 6-multiwell 
plates were coated with 1,2% Poly-HEMA (2-hydroxyethylmethacrylate) (Sigma) 
solution and sored at 4oC. Cells were trypsinized, resuspended in PBS and 
centrifuged at 1200 rpm for 5 minutes. Pellet was resuspended in PBS and PKH-
26 dye (Sigma) diluted 1:20000 and incubated for 5minutes at room temperature. 
Cells were centrifuged and resuspended in stem cell medium and counted. A 
cellular suspension of 20000 cells/ml was prepared and 2m were plated in 6-
multiwell plates in quadruplicates (4000 cells/well), and incubated at 37°C for one 
week. After one the mammospheres were observed at fluorescent microscope and 
only mammospheres containing one PKH26-labelled cell inside the spheres were 
counted. The no-labelled mammospheres and spheres containing more than one 
PKH26-positive cells where considered respectively spheres originating from 
differentiated/precursor cells and cellular aggregates. 
6.5 E-cadherin internalization assay 
E-cadherin internalization assay was performed using an anti-Ecadherin antibody 
(HECD-1) from Abcam, recognizing the extracellular domain of E-cadherin. Briefly, 
MCF10A cells were plated on coverslip at about 30% of confluency. The day after 
cells were starved overnight by incubating them with culture medium containing 
only serum (horse serum 5%). After starvation, cells on coverslips were washed 
with PBS and incubated with the anti-E-cadherin antibody (2µg/ml) for 1h at 4oC. 
 After 1h incubation, time zero cells were fixed with PFA 4% for 10 minutes. 
For the remaining samples, PBS washes were performed and cells were 
incubating with culture medium containing serum and TGFβ (5ng/ml) for 90 and 
180 minutes. After incubation cells were fixed with PFA 4% for 10 minutes. 
Immunofluorescence was performed. Coverslips were washed with PBS and 
 
 
57 
permeabilized in PBS 0.1% Triton X-100 for 10 min at room temperature. To 
prevent non-specific binding of the antibodies, cells were incubated with PBS in 
the presence of 5% BSA for 30 min.  
 The coverslips were incubated with primary polyclonal anti-Epn3 antibody 
(rabbit, produced in house) diluted in PBS 0.2 % BSA. After 1 hour of incubation at 
room temperature, coverslips were washed with PBS. Cells were then incubated 
for 1h at room temperature with secondary anti-mouse antibody Cy3 (Amersham) 
to detect E-cadherin and anti-rabbit Alexa 488-conjugated (Molecular Probes) to 
detect Epn3. After washes in PBS, coverslips were mounted in a 90% glycerol 
solution containing diazabicyclo-(2.2.2)octane antifade (Sigma) and examined 
under a confocal immunofluorescence microscope (Leica). Images were further 
processed with the Adobe Photoshop software (Adobe) or with Image J to merge 
the images of the single channels. 
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AIMS AND RATIONALE OF THE STUDY 
The starting point for the research presented in this thesis was provided by a 
preliminary gene expression analysis conducted in our lab to identify novel genes 
that might contribute to poor prognosis in breast cancer. In this preliminary study, 
the endocytic protein Epn3 was found to be part of a gene signature associated 
with metastatic relapse in breast cancer patients. Based on these preliminary data, 
we hypothesized that Epn3 might have a pathogenetic role in this malignancy. 
Given the emerging data supporting a crosstalk between endocytosis, signaling 
and cancer (see Introduction, sections 1.1 and 1.2), it is possible that Epn3 exerts 
an oncogenic activity through an endocytosis-based mechanism (although we do 
not exclude that a non-endocytic function might also be relevant to the putative 
role of Epn3). Indeed, several endocytic proteins are abnormally expressed in 
human cancers and, for some of them, a causative link between altered trafficking 
and tumorigenesis has been demonstrated. Therefore, a hot topic in the endocytic 
field is to demonstrate whether deregulation of internalization processes can 
promote tumor initiation. In light of this scenario, we were interested in clarifying 
the role of Epn3 in breast tumorigenesis, which could provide additional evidence 
to support a strong connection between endocytosis and cancer. 
An additional relevant aspect that emerged from our preliminary study was 
the potential prognostic value of Epn3 in breast cancer that, if confirmed, might 
contribute to a more refined clinical management of breast cancer patients. 
Indeed, the identification of novel biomarkers and new therapeutic targets to better 
stratify breast cancer patients seems to be the major need in the clinical 
management of this type of cancer. Advanced technologies have allowed the 
generation of gene expression profiles that have prognostic power and can bring 
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therapeutic benefits to patients. Nevertheless, to allow the development of proper 
patient stratification tools that can be easily used in the clinical setting the 
identification of novel prognostic biomarkers from these signatures is currently 
needed. 
In line with our rationale, the first aim of the study presented in this thesis 
was to assess the clinical value of Epn3 as a prognostic marker. To this end, we 
performed IHC analysis on large cohorts of breast cancer patients to evaluate the 
correlation of Epn3 with classical clinical parameters of breast cancer and its 
ability to predict clinical outcome and patient survival (See Results, section 1).  
The second aim was to validate the role of Epn3 in breast tumorigenesis by 
exploiting in vitro and in vivo assays to study cell transformation and tumorigenic 
potential upon Epn3 ablation or overexpression (see Results, section 2).  
Finally, the third goal was to investigate the molecular mechanisms 
underlying Epn3 function in breast cancer and normal cells to uncover whether 
Epn3 exerts its oncogenic properties through an endocytic function, which could 
interfere with one or more signaling pathways (see Results, section 3). 
Results from the proposed study should allow us to define whether Epn3 
overexpression has a causal role in breast cancer, as well as provide valuable 
insights into the molecular mechanisms through which Epn3 could contribute to 
breast tumorigenesis. In a future perspective, our results could also lead to the 
identification of novel therapeutic targets and to a better clinical management of 
breast cancer patients. 
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RESULTS 
1 Analysis of Epn3 expression in human breast tumors 
1.1 Epn3 expression correlates with aggressive clinical/pathological 
parameters in invasive breast tumors 
In a previous preliminary study performed in our lab with the aim of screening for 
novel genes contributing to poor prognosis in breast cancer, a transcriptional 
profile associated with metastatic relapse in breast cancer patients was derived 
(unpublished data). In this study, the Affimetrix GeneChip platform was used to 
perform gene expression analysis of tumors from 70 patients with node-negative 
primary breast carcinomas. This patient cohort included surgical patients who 
developed metastases within 5 years (29 cases) and patients who continued to be 
disease-free (41 cases) after 12 years. The analysis of the genes differentially 
expressed between these two groups generated a gene signature prognostic for 
metastasis, in which EPN3 was included. EPN3 was overexpressed in 20% of the 
breast tumors analyzed and in 45% of the poor-prognosis cases. These 
preliminary observations argued for a possible role for Epn3 as prognostic marker 
in breast cancer and prompted us to further investigate this hypothesis.  
To assess the clinical relevance of Epn3 expression in breast cancer, we 
investigated the correlation between Epn3 expression in breast cancer patients 
and clinical/pathological parameters and disease outcome. To this purpose, we 
decided to analyze larger patient cohorts by immunohistochemistry (IHC) on 
breast tumor tissue microarray (TMAs), already available in our lab. 
To define the parameters for Epn3 quantification, we evaluated the 
expression of Epn3 on normal breast tissues (n=31) using a specific anti-Epn3 
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antibody (“VI31” monoclonal antibody) that was produced in-house since 
commercial anti-Epn3 antibodies were not available to perform a comprehensive 
Epn3 protein expression analysis. Normal breast tissue samples showed very low 
levels of Epn3 expression (median score=0.5), which lead us to define tumors with 
high Epn3 expression as those displaying an expression score >1 (Figure 6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 | Immunohistochemical analysis of Epn3 expression in human 
breast tumor samples  
Immunohistochemical (IHC) analysis of Epn3 expression was performed on 
formalin-fixed paraffin-embedded breast tumor and normal tissue sections (2µm) 
using the VI31 anti-Epn3 antibody produced in-house.   
A representative image of a normal breast tissue section expressing low levels of 
Epn3 (score=0.5) is shown. Three representative images of tumor samples 
showing different levels of Epn3 expression (scores from 1 to 3) are shown. 
Tumors with high Epn3 expression were defined as those displaying an 
expression score >1. According to the score assigned, tumors were classified as 
EPN3-high and EPN3-low. Scale bar 300µm 
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 Epn3 protein levels were then analyzed by IHC on 2 independent case 
collections: one ‘case control’ group – composed of 349 patients who developed 
an event, including loco-regional relapse and distant metastasis after the first 
breast cancer surgery (also referred to as training set,  
Table 1) – and one ‘validation’ group – comprising 916 consecutive cases (our test 
set, Table 2). In the case-control cohort, Epn3 expression was high in 
approximately 30% of tumors (92 out of 298 analyzable cases). Elevated Epn3 
levels significantly correlated with many clinical and pathological parameters 
indicative of aggressive disease, such as tumor size (pT), node positive status, 
high grade (GRADE), PgR negative status, high proliferative index (Ki67) and 
HER2 positive status (Table 3). Moreover, there was a significant association with 
the more aggressive molecular subtypes, such as Luminal B and triple negative 
(TNBC) tumors [111, 137] (Table 3). Finally, high expression of Epn3 correlated 
with any event of disease relapse, distant metastasis and death (Table 3).  
To refine our analysis, we analyzed the expression of Epn3 on the 
consecutive group (Table 2). In this group, we confirmed the association between 
high Epn3 levels and high grade, hormone receptor negative tumors (ER and 
PgR), high Ki67 and positive HER2 status as well as the different molecular 
subtypes (Luminal B, Luminal B-HER2+, HER2+ and triple negative) (Table 4).  
Altogether these results indicate the Epn3 expression is associated with 
prognostic markers of aggressive breast cancer, disease recurrence and survival, 
suggesting a clinical value for Epn3 detection in breast cancer.  
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CASE-CONTROL Cohort (N = 349) 
Parameter Group N % 
Histotype  
Ductal 290 83,09 
Lobular 50 14,33 
Mixed/Other 9 2,58 
Age at Surgery  
<50 171 49 
!50 178 51 
pT 
pT1 178 51,44 
pT2 142 41,04 
pT3 18 5,2 
pT4 8 2,3 
Grade 
G1 56 18,42 
G2 132 43,42 
G3 116 38,16 
Ki67 Status 
LOW 116 34,42 
HIGH 221 65,58 
HER2 Status 
NEG 227 88,22 
POS 37 11,78 
Nodal Status 
NEG 153 43,84 
POS 196 56,16 
ER Status 
NEG 106 31,45 
POS 231 68,55 
PgR Status 
NEG 140 41,54 
POS 197 58,46 
Subtype 
LUMINAL A 88 28,85 
LUMINAL B 129 42,3 
HER2 POS 23 7,54 
LUM B HER2 POS 10 3,28 
TNBC 55 18,03 
Any Event  
ANY 196 56,16 
NONE 153 43,84 
Distant event  
DISTANT 244 69,92 
NONE 105 30,09 
Status 
Alive 233 66,76 
Dead  116 33,24 
  
Table 1 | Clinical and pathological information of the case-control dataset of 
breast cancer patients 
The clinical and pathological information of the patients included in the case-
control TMA is reported. These patients have undergone surgery at the European 
Institute of Oncology (IEO) between 1994 and 1997. Disease recurrence (any and 
distant relapse) was within 18 years. Any Relapse: loco-regional relapse, distant 
metastasis; Distant Relapse: distant metastasis; secondary primary cancer and 
contralateral breast cancer were not considered as a primary tumor related event. 
For some patients not all information was available. 
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CONSECUTIVE Cohort (N=916) 
Cohort Group N % 
Histotype  
Ductal 728 79,48 
Lobular 102 11,14 
Mixed/Other 86 9,39 
Age at Surgery  
<50 410 44,76 
!50 506 55,24 
pT 
pT1 85 9,28 
pT2 756 82,53 
pT3 63 6,88 
pT4 12 1,31 
Grade 
G1 68 7,74 
G2 340 38,68 
G3 471 53,58 
Ki67 Status 
LOW 169 18,47 
HIGH 746 81,53 
HER2 Status 
NEG 797 88,95 
POS 99 11,05 
Nodal Status 
NEG 306 33,89 
POS 597 66,11 
ER Status 
NEG 199 21,72 
POS 717 78,28 
PgR Status 
NEG 310 33,84 
POS 606 66,16 
Subtype 
LUMINAL A 162 18,1 
LUMINAL B 508 56,76 
HER2 POS 49 5,47 
LUM B HER2 POS 50 5,59 
TNBC 126 14,08 
Any Event  
ANY 272 29,69 
NONE 644 70,31 
Distant event  
DISTANT 245 26,75 
NONE 671 73,25 
Status 
Alive 664 72,49 
Dead  252 27,51 
    
  
Table 2 | Clinical and pathological information of the consecutive cohort of 
breast cancer patients 
The clinical and pathological information of the patients included in the 
consecutive cohort is reported. These patients have undergone surgery at the 
European Institute of Oncology (IEO) between 1997 and 2000. Disease 
recurrence (any and distant relapse) was within 18 years. Any Relapse: loco-
regional relapse, distant metastasis; Distant Relapse: distant metastasis; 
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secondary primary cancer and contralateral breast cancer were not considered as 
a primary tumor related event. For some patients not all information was available.  
CASE-CONTROL COHORT (N = 349*) 
  EPN3 LOW EPN3 HIGH  
All Patients (298*) 206 92 (30.87%) Pvalue  
Histotype Ductal 163 86 (34.54%)  
 Lobular 35 5 (12.50%) 0.0053 
pT 1 116 38 (24.68 %)  
 2-3-4 89 53 (37.32%) 0.0185 
Nodal Status NEG 102 24 (19.05 %)  
 POS 104 68 (39.53 %) 0.0002 
GRADE G1 45 6 (11.76 %)  
 G2 80 29 (26.61 %)  
 G3 54 52 (49.06 %) <0.0001 
ER POS 144 56 (28 %)  
 NEG 57 33 (36.67 %) 0.1388 
PgR POS 128 43 (25.15 %)  
 NEG 73 46 (38.66 %) 0.0141 
Ki67 LOW 82 13 (13.68 %)  
 HIGH 119 76 (38.97 %) <0.0001 
HER2 NEG 181 70 (27.89 %)  
 POS 15 17 (53.13 %) 0.0036 
LUMINAL A 68 9 (11.69%)  
LUMINAL B 77 44 (36.36%)  
LUMINAL B HER2 
POS 
6 3 (33.33%)  
HER2 POS 7 12 (63.16%)  
TNBC 34 16 (32%) <0.0001 
Distant 
Relapse NO 162 47 (22.49 %)  
 YES 44 45 (50.56 %) <0.0001 
Any Relapse NO 139 30 (17.75 %)  
 YES 67 62 (48.06 %) <0.0001 
Status Alive 157 44 (21.89 %)  
 Dead 49 48 (49.48 %) <0.0001 
  
Table 3 | Correlation of Epn3 expression and clinico-pathological parameters 
in the case-control cohort of 349 breast cancer patients 
Epn3 expression was measured by IHC on TMA using the anti-Epn3 VI31 
antibody. Tumors with high Epn3 status (EPN3 HIGH) display an expression score 
>1, while low Epn3 status (EPN3 LOW) tumors show an expression score <1. 
Asterisks indicate that the number of scored cases (298) is lower than the total 
number of cases (349). Scoring of samples was not possible when individual cores 
detached from the slides during experimental manipulation and when clinical 
information was not available. 
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CONSECUTIVE COHORT (N = 916*) 
  EPN3 LOW EPN3 HIGH  
All Patients (762*) 479 283 (37.14%) P value  
Histotype Ductal 365 258 (41.41%)  
 Lobular 62 13 (17.33%)  
 Other/Mixed 52 12 (18.75%) <0.0001 
pT 1 51 22 (30.14 %)  
 2-3-4 428 261 (37.88%) 0.1929 
Nodal Status NEG 170 84 (33.07 %)  
 POS 299 199 (39.96%) 0.0651 
GRADE G1 47 5 (9.62 %)  
 G2 209 67 (24.28 %)  
 G3 199 205 (50.74 %) <0.0001 
ER POS 395 201 (33.72 %)  
 NEG 84 82 (49.40 %) 0.0002 
PgR POS 328 172 (34.40 %)  
 NEG 151 111 (42.37 %) 0.0306 
Ki67 LOW 116 16 (12.12 %)  
 HIGH 362 267 (42.45 %) <0.0001 
HER2 NEG 445 225 (33.58 %)  
 POS 28 55 (66.27 %) <0.0001 
LUMINAL A 113 16 (12.40%)  
LUMINAL B 270 162 (37.50%)  
LUMINAL B HER2 POSITIVE 12 29 (70.73%)  
HER2 POSITIVE 16 26 (61.90%)  
TNBC 61 47 (43.52%) <0.0001 
!
 
Table 4 | Correlation of Epn3 expression and clinico-pathological parameters 
in the consecutive cohort of 916 breast cancer patients 
Epn3 expression was measured by IHC on TMA using anti-Epn3 VI31 antibody. 
Tumors with a high Epn3 status (EPN3 HIGH) display an expression score >1, 
while low Epn3 status (EPN3 LOW) tumors show en expression score <1. 
Asterisks indicate that the number of scored cases (762) is lower than the total 
number of cases (916). Scoring of samples was not possible when individual cores 
detached from the slides during experimental manipulation and when clinical 
information was not available. 
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1.2 Epn3 expression is associated with high risk of breast cancer 
recurrence and poor disease outcome 
Since Epn3 overexpression is associated with indicators of aggressive breast 
cancer, we decided to investigate whether Epn3 status could be a prognostic 
marker able to predict disease recurrence and survival in breast cancer patients. 
 In the case-control group, we found that Epn3 overexpression is 
significantly correlated with high risk of disease recurrence (any or distant relapse) 
and death (Table 3).  
To validate the prognostic potential of Epn3 observed in the case-control 
cohort, we performed Kaplan-Meier analysis on the consecutive cohort of 916 
patients (Table 2). Tumor patients were stratified on the basis of their Epn3 
expression levels in high (score >1) and low (score <1) Epn3 status. Kaplan-Meier 
curves of disease-free survival and overall survival revealed that high Epn3 status 
correlates with increased risk of disease relapse (p=0.001) and decreased overall 
survival (p=0.0028) (Figure 7)  
Since HER2 is one of the most amplified oncogene in breast cancer 
strongly associated with poor outcome [124, 138] (see also Discussion, section 
1.1) we tested whether Epn3 can retain its prognostic value independent of HER2 
status. We analyzed the association between Epn3 status and survival in the 
subpopulation of HER2-negative patients present in the consecutive cohort. Also 
in this case, our results confirmed an inverse correlation between Epn3 expression 
and disease-free survival (p=0.0003) and overall survival (p=0.0018) (Figure 8). 
Together, our data identify Epn3 overexpression as a new prognostic 
marker in breast cancer. This marker significantly correlates with high risk of 
disease recurrence and fatal outcome. Importantly, Epn3 retains its prognostic 
value independently of HER2 status in breast cancer patients.  
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Figure 7 | Cumulative incidence probability of disease-free survival and 
overall survival in the consecutive cohort 
Kaplan-Meier plots of the 10-years cumulative incidence probability of disease-free 
survival and overall survival according to low (LOW, score <1, red line) and high 
(HIGH, score >1, blue line) Epn3 expression measured by IHC in the consecutive 
cohort of 916 breast cancer patients. P-values (P) are indicated.  
 
 
Figure 8 | Cumulative incidence probability of disease-free survival and 
overall survival in HER2-negative patients of the consecutive cohort 
Kaplan-Meier plots of the 10-years cumulative incidence probability of disease-free 
survival and overall survival according to low (LOW, score <1, red line) and high 
(HIGH, score >1, blue line) Epn3 expression measured by IHC in HER2-negative 
patients of the consecutive cohort of 916 breast cancer patients. P-values (P) are 
indicated. 
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1.3 The EPN3 gene is amplified in human breast tumors 
Gene amplification is one of the molecular mechanisms that lead to oncogene 
activation [139]. To assess whether the EPN3 gene is amplified in breast tumors, 
we performed dual color interphase fluorescence in situ hybridization (FISH) 
analysis on human breast tumor biopsies. The EPN3 gene is located on 
chromosome 17, a chromosome very relevant to breast tumorigenesis since one 
of the most frequently amplified breast oncogenes, HER2, is located there. Of 
note, EPN3 and HER2 are located in the 17q12-21 region, which is frequently 
rearranged in breast cancers, approximately 12M base pairs apart from each other 
[140, 141] (Figure 9A). Thus, we were also interested in understanding whether 
these genes were co-amplified in the analyzed tumors. 
We used a BAC clone encompassing the EPN3 gene and a HER2 gene 
probe to detect EPN3 and HER2 gene amplification, respectively, in a subset of 
281 breast tumors. We observed EPN3 gene amplification in approximately 18%, 
and HER2 amplification in 15% of the total samples analyzed (Figure 9B). Despite 
the observation that co-amplification of the two genes occurred to some extent, 
our results show that HER2 and EPN3 amplifications are independent events. 
Indeed, 66% of EPN3-amplified tumors did not show HER2 amplification while 
60% of HER2-amplified cases did not display EPN3 amplification. These results 
are in line with previous data showing that these two amplicons can be amplified 
independently [142]. 
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These data indicate that EPN3 is amplified in a subset of breast tumors and, 
together with the observation that Epn3 overexpression has a potential prognostic 
value in breast cancer patients - including those with HER2-negative status - 
strongly suggest that the involvement of Epn3 in cancer progression could be both 
dependent and independent from HER2 status. 
 
 
 
 
Figure 9 | Analysis of EPN3 gene amplification in human breast tumor 
samples 
A) Scheme of chromosome 17. The EPN3 gene is located in chromosome 17, 
12.4 Mb from the HER2 gene. B) Representative scheme of EPN3 and HER2 
gene-amplified samples as assessed by FISH analysis in 281breast tumor 
samples. Venn diagram shows the overlap between EPN3-FISH and HER2-FISH 
data. Both EPN3 and HER2 genes were considered amplified when the ratio 
between each specific gene and the chromosome 17 centromere copy number 
was >2.25. Significance of the co-amplification was calculated with Fisher’t.  
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2 Characterization of the role of Epn3 in breast tumorigenesis 
To identify suitable cell model systems to investigate the role of Epn3 in breast 
tumorigenesis, we analyzed the expression of the protein in a panel of 
commercially available human normal and tumor breast cell lines, both by western 
blot (WB) and quantitative PCR (Q-PCR) analysis. We observed that Epn3 is 
highly expressed in two breast tumor cell lines, BT474 and MDA-MB361, in 
comparison to the normal breast cell lines, MCF10A and HMEC, both at the 
protein and mRNA level (Figure 10A,B).  
We then assessed whether Epn3 overexpression in the BT474 and MDA-
MB361 cell lines was due to gene amplification, as observed in human breast 
tumor samples (Figure 10). We performed dual color FISH analysis on metaphase 
chromosomes, using a centromeric probe for chromosome 17 and a BAC clone 
encompassing the EPN3 gene, and observed that EPN3 is indeed amplified in 
both BT474 and MDA-MB361 cells (Figure 11).  
Based on these results, we selected different cell lines to be used as model 
systems in the analysis of the involvement of Epn3 in breast tumorigenesis: i) the 
BT474 breast tumor cell line, which overexpresses Epn3 due to gene 
amplification, was chosen to study the dependence of tumorigenic phenotypes on 
EPN3 locus alteration; ii) the normal breast epithelial cell line MCF10A and the 
breast tumor cell lines HCC1569 and MCF7 - which express low levels of Epn3 
and do not show EPN3 amplification – were selected to uncover the transforming 
potential of Epn3 overexpression.   
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Figure 10 | Analysis of Epn3 expression in a panel of human breast normal 
and tumor epithelial cell lines 
A) Epn3 expression in human normal mammary epithelial cell lines (N) and human 
breast tumor epithelial cell lines (T) was evaluated by western blot (WB) analysis 
using VI31 antibody. Vinculin was used as loading control. B) Expression of EPN3 
transcript levels was examined with Q-PCR analysis in normal mammary cell lines 
(N) and some of the breast tumor (T) cell lines. Results were normalized to the 
housekeeping gene 18S and are expressed as fold-change relative to MCF10A 
cells. Results represent the mean ± SD of an experiment performed in triplicate. 
 
 
 
 
 
 
 
 
Figure 11 | Analysis of EPN3 gene amplification in breast cell lines 
EPN3 gene amplification evaluated by FISH analysis on metaphase chromosomes 
in MCF10A, BT474 and MDA-MB 361 cells. A centromeric probe for chromosome 
17 (green) and a BAC clone for EPN3 gene (red) were used. DAPI was used for 
nuclei staining. EPN3 gene was considered amplified when the ratio EPN3/Chr.17 
was >2-fold. At least three nuclei per sample were analyzed. Representative 
images at 100x magnification are shown. 
Chromosome 17
EPN3 gene
MCF10A BT474 MDA-MB 361
 
 
73 
2.1 Functional characterization of Epn3 ablation in breast tumor cells 
carrying EPN3 gene amplification 
2.1.1 Epn3 is required for in vitro anchorage-independent growth of breast 
tumor BT474 cells  
To shed light on the role of Epn3 in breast carcinogenesis, we stably silenced 
Epn3 expression in BT474 cells, and analyzed the consequences of this genetic 
manipulation on tumorigenic phenotypes.  
We used a lentiviral vector system encoding two short-hairpin RNA (shRNA) oligos 
targeting Epn3 (shEpn3#1 and shEpn3#2) to stably knockdown (KD) Epn3 in 
BT474 cells. As controls, we used a shRNA targeting luciferase (shLUC) or a 
shRNA mismatch sequence (shMis) (see Materials and Methods). Both Epn3-
shRNA yielded efficient ablation of Epn3 expression as assessed by WB analysis 
(Figure 12A). We performed a soft agar assay and we found that Epn3 ablation in 
BT474 cells strongly impaired the capacity of these cells to grow in an anchorage-
independent manner, causing a reduction in the number and size of colonies 
formed in semi-solid medium (~2-fold reduction in BT474 Epn3-KD cells in 
comparison to control cells, p<0.05) (Figure 12B) 
To provide a direct evidence of the specific role of Epn3 overexpression 
driven by gene amplification in the tumorigenic capacity of breast tumor cells, we 
decided to silence Epn3 in MCF7 breast tumor cells, which show basal levels of 
Epn3 without any alteration of EPN3 locus (Figure 10), in order to perform a 
comparative phenotytpic analysis between BT474 and MCF7 Epn3-KD cells.  
We stably silenced Epn3 expression in MCF7 cells by infecting these cells 
with the same lentiviral systems used in BT474 cells. As for BT474 cells, we 
obtained a good Epn3 KD efficiency in MCF7 cells, as assessed by WB analysis 
(Figure 13A). However, contrary to the results obtained in BT474, we found that 
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ablation of Epn3 in MCF7 did not affect colony formation in the soft agar assay 
(Figure 13B).  
These results indicate that Epn3 ablation selectively impairs the anchorage-
independent growth of cells harboring EPN3 gene amplification, such as BT474, 
while it does not significantly affect the growth of tumor cells with physiological 
Epn3 levels.  
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Figure 12 | Effect of Epn3 ablation on anchorage-independent growth of 
BT474 cells 
BT474 cells were infected with lentiviral vectors (pSICOR) expressing shRNAs 
targeting Epn3 (shEpn3#1, shEpn3#2). Lentiviral vectors encoding a shRNA 
targeting luciferase (shLUC) and a mismatch shRNA (shMis) were used as 
negative controls. A) Efficiency of stable silencing in BT474 was assessed by WB 
analysis using VI31 antibody. Vinculin was used as loading control. B) The 
anchorage-independent growth of BT474-infected cells was assessed using the 
soft agar assay. Cells (25,000) were plated in 6-well culture plates in a medium 
containing 0.3% agar. After 3 weeks in culture, colonies were counted by bright-
field microscopy at 4x magnification. Bar graphs report mean colony number per 
well  ± SD of an experiment performed in triplicate and are representative of 3 
independent experiments. Asterisks indicate mean p-value < 0.05 compared to 
shLUC and shMis. C) Representative bright-field microscopy images of soft-agar 
colonies formed by BT474-infected cells are shown. Magnification 4x. Scale bar 
100 µm. 
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Figure 13 | Effect of Epn3 ablation on anchorage-independent growth of 
MCF7 cells 
MCF7 cells were infected with lentiviral vectors (pSICOR) expressing shRNAs 
targeting Epn3 (shEpn3#1, shEpn3#2). Lentiviral vectors encoding a shRNA 
targeting luciferase (shLUC) and a mismatch shRNA (shMis) were used as 
negative controls. A) Efficiency of stable silencing in MCF7 cells was assessed by 
WB analysis using VI31 antibody. Vinculin was used as loading control. B) The 
anchorage-independent growth of MCF7-infected cells was assessed using the 
soft agar assay. Cells (25,000) were plated in 6-well culture plates in a medium 
containing 0.3% agar. After 3 weeks in culture, colonies were counted by bright-
field microscopy at 4x magnification. Bar graphs report mean colony number per 
well  ± SD of an experiment performed in triplicate and are representative of 3 
independent experiments. C) Representative bright-field microscopy images of 
soft-agar colonies formed by MCF7-infected cells are shown. Magnification 4x. 
Scale bar 100 µm. 
 
 
 
2.1.2 Epn3 is required for in vivo tumorigenic growth of breast tumor BT474 
cells   
Based on the in vitro results, we next investigated the effects of Epn3 ablation on 
the in vivo tumorigenic potential of BT474 cells.  
To this aim, 3x105 BT474 Epn3-KD cells were orthotopically injected into 
the inguinal mammary fat pad of NOD/SCID female immunocompromised mice. 
As a control, we injected BT474 control (3x105 BT474 shLUC) cells into the 
contralateral mammary gland. Eleven weeks post-injection, tumors reached a 
palpable size (~100mm3) and were monitored every 7 days for another 3 weeks. 
Remarkably, tumors derived from Epn3-KD BT474 cells grew slower and were ~2-
fold smaller in comparison with tumors generated by control BT474 cells (Figure 
14A,B). To assess the Epn3 expression levels on the tumors extracted from the 
mammary gland, we dissociated them into cells and performed WB analysis. We 
observed that the efficiency of Epn3 ablation in tumors was the same as the one 
obtained in parental Epn3 KD cells (Figure 14C). 
 
 
77 
Our results show that BT474 cells are dependent on altered Epn3 
expression for the maintenance of their malignant phenotype.  
 
 
 
 
Figure 14 | Effect of Epn3 ablation on in vivo tumor growth of BT474 cells 
Mammary tumors were generated by injecting 300 000 Epn3-KD cells (shEpn3#1) 
and control (shLUC) BT474 cells into the inguinal mammary fat pads of female 
NOD/SCID IL2 gamma-chain null mice. Tumors were grown for 13 weeks before 
being explanted. A) Kinetic evaluation of BT474 shLUC and shEpn3#1 tumor 
growth. Tumor volume was assessed by in vivo caliper measurements at the 
indicated time points after injection. Asterisks indicate mean p-value < 0.05 (*) and 
< 0.01 (**) compared to shLUC. B) The distribution of tumor volume of BT474 
shLUC and shEpn3#1 is reported in a box-plot. Representative images of tumor 
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outgrowths are reported below the chart. C) The expression of Epn3 in mammary 
tumors was assessed by WB analysis using VI31 antibody. Vinculin was used as 
loading control. Results are representative of 2 experiments (n=8) and represent 
the mean± SEM. 
 
 
2.2 Functional characterization of Epn3 overexpression in normal and 
tumor breast cell lines 
2.2.1 Epn3 overexpression induces EMT and invasive phenotype in normal 
breast epithelial MCF10A cells 
To investigate the molecular mechanisms through which Epn3 can induce breast 
tumorigenesis, we overexpressed Epn3 in normal MCF10A cells, which display 
low basal levels of Epn3 and show no alterations at the level of the EPN3 locus. 
To this purpose, we used a retroviral vector system expressing Flag-tagged Epn3 
(pBABE-Epn3). To make sure we could observe an Epn3-specific induced 
phenotype, we also transfected cells with Flag-tagged Epn1 (pBABE-Epn1), a 
member of the Epsin family that is not amplified in breast tumors (see Discussion, 
sections 1.2 and 4). Cells infected with empty vector (pBABE) were used as a 
negative control. We obtained high levels of Epn3 expression in the MCF10A cells, 
which were comparable to the levels observed in BT474 cells (Figure 15A, lanes 
a, b and c). Furthermore, we obtained the same level of Epn3 and Epn1 
overexpression, as determined by anti-Flag WB analysis (Figure 15A, lanes c and 
d).  
Before we were able to perform some tumorigenic assays (i.e. soft agar), 
we immediately observed that Epn3 overexpression induced a marked alteration 
of cell morphology in 2D-culture. Indeed, pBABE-Epn3 cells, but not pBABE-Epn1 
cells, acquired a more elongated and spindle-like morphology compared to the 
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cobblestone-like epithelial morphology of pBABE cells (Figure 15B). These 
morphological changes were suggestive of EMT in pBABE-Epn3 cells. EMT is a 
complex cellular process in which polarized epithelial cells progressively lose their 
epithelial properties and acquire a mesenchymal phenotype characterized by the 
expression of specific mesenchymal genes, increased invasiveness and migration 
(reviewed in [143]). 
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Figure 15 | Analysis of the effects of Epn3 overexpression in human normal 
mammary epithelial MCF10A cells 
A) MCF10A cells were infected with retroviral vectors expressing Flag-Epn3 
(pBABE-Epn3, lane c) or Flag-Epn1 (pBABE-Epn1, lane d). Cells infected with 
empty vector (pBABE, lane b) are used as negative control. Expression of Epn3, 
Epn1 (upper band) and Flag was examined by WB analysis. BT474 cells were 
used as positive control for Epn3 expression (lane a). GAPDH was used as a 
loading control. B) The morphology of MCF10A cells expressing control vector 
pBABE, pBABE-Epn1, pBABE-Epn3 or pBABE-mTwist was assessed by phase 
contrast microscopy. Representative images are shown. Magnification 4x. C) The 
overexpression of mTwist in MCF10A cells was evaluated by Q-PCR analysis. 
Data were normalized to the housekeeping gene GAPDH and are expressed as 
fold-change relative to pBABE cells. Results represent the mean ± SD of an 
experiment performed in triplicate.  
 
 
 
 
To better investigate this phenotype, we generated MCF10A cells 
overexpressing the transcriptional factor Twist by transfecting them with retroviral 
vector expressing murine Twist (pBABE-mTwist). Twist is a well-known EMT-
inducer gene and therefore represents a good positive control for induction of EMT 
phenotype [144]. We obtained high level of Twist overexpression in MCF10A as 
assessed by Q-PCR analysis (Figure 15C). By comparing pBABE-Epn3 and 
pBABE-mTwist cells at the morphological level, we observed a similar fibroblast-
like shape in both cell types (Figure 15B). However, pBABE-mTwist cells were 
more scattered than pBABE-Epn3 cells suggesting a more advanced EMT 
phenotype. 
To assess if this was the case, we analyzed the expression of known EMT 
markers, namely N-cadherin, Vimentin and E-cadherin. By performing WB and Q-
PCR analysis, we observed higher levels of N-cadherin and vimentin expression in 
pBABE-Epn3 and pBABE-mTwist than in pBABE and pBABE-Epn1 cells (Figure 
16A,B). On the contrary, E-cadherin protein expression was reduced in both 
pBABE-mTwist and pBABE-Epn3 cells (Figure 16A).  
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This “cadherin switch” is a known hallmark of EMT. Indeed, EMT is usually 
associated with a switch from E-cadherin to N-cadherin, which is expressed by 
mesenchymal cells, cancer cells and neural tissue (reviewed in [145]). Moreover, 
overexpression of N-cadherin is found in some carcinoma cells with decreased 
levels of E-cadherin; in these cells, N-cadherin acts as a weak intercellular 
adhesion molecules, promoting EMT progression and cell motility [146]. Of note, 
only Twist overexpression, but not Epn3, caused a reduction in the E-cadherin 
mRNA levels, suggesting that Twist and Epn3 may affect E-cadherin expression 
levels through distinct mechanisms. 
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Figure 16 | Epn3 overexpression induces EMT phenotype in normal 
mammary epithelial MCF10A cells. 
A) Expression of epithelial marker E-cadherin and the mesenchymal markers N-
cadherin and vimentin was examined by WB in MCF10A cells expressing pBABE, 
pBABE-Epn1, pBABE-Epn3 or pBABE-mTwist. GAPDH was used as a loading 
control. B) Expression of epithelial E-cadherin, mesenchymal N-cadherin and 
Vimentin transcripts was examined by Q-PCR. Data were normalized to the 
housekeeping gene 18S and are expressed as fold-change relative to pBABE 
cells. Results represent the mean ± SD of an experiment performed in triplicate. C) 
Immunofluorescence staining of E-cadherin in MCF10A-infected cells cultured at 
confluency for 48 h. Green signal represents E-cadherin and blue signal 
represents nuclear staining by DAPI. White asterisks indicate cells lacking E-
cadherin staining. 
 
 
 
 
We next assessed E-cadherin expression at the cell-cell junctions by 
immunofluorescence (IF). We observed that E-cadherin expression was lost in a 
non-homogeneous way in both pBABE-Epn3 and pBABE-mTwist cells (Figure 
16C). Moreover, upon Epn3 overexpression in the cells that still presented E-
cadherin staining there was a marked rearrangement of E-cadherin at cell-cell 
junctions with the formation of comb-like structures with many radially oriented 
strands (Figure 16C), a phenotype that has been previously associated with a pre-
EMT state [147]. On the contrary, E-cadherin appeared as a continuous belt 
between cells in pBABE and pBABE-Epn1 samples. These results suggest an 
alteration of cell-cell adherent junctions in pBABE-Epn3 cells that could be 
important for cell invasion and migration.  
Since pBABE-Epn3 cells appear to have acquired characteristics of highly 
motile cells, we assessed their invasiveness. Cells were seeded on the top 
chamber of a transwell on a layer of Matrigel and cell invasion into this layer was 
assessed by crystal violet staining (see Material and Methods, section 6.3).  
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We observed that pBABE-Epn3 cells display ~50% increase of the 
capcacity of invading the Matrigel layer than pBABE control cells (Figure 17).  
Taken together these data indicate that Epn3 overexpression in normal 
mammary epithelial MCF10A cells is able to induce an EMT-like phenotype 
characterized by changes in cell morphology, increased expression of 
mesenchymal markers, alteration of cell-cell junctions, and increased 
invasiveness.  
 
                              
0
0,02
0,04
0,06
0,08
0,1
pBABE pBABE-Epn3Ce
ll d
en
sit
y A
U 
(A
BS
 5
95
nm
)
*
50µm
 
 
Figure 17 | Epn3 overexpression increases invasiveness of normal 
mammary epithelial MCF10A cells 
Matrigel invasion assay of pBABE and pBABE-Epn3 MCF10A cells was performed 
by plating 40,000 cells in transwell chambers on a layer of growth factor reduced 
Matrigel. After 24 h of incubation cells that had invaded the Matrigel layer were 
stained with crystal violet. Membranes stained with crystal violet were then 
dissolved in acetic acid and absorbance was measured at 595nm. Bar graph 
reports mean absorbance at 595nm ± SD of an experiment performed in 
quadruplicate and is representative of two independent experiments. Asterisk 
indicates a p-value < 0.05. Representative images are shown below the graph. 
Magnification 20x. Scale bar 50 µm. 
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2.2.2 Epn3 overexpression causes an expansion of the stem cell 
compartment in normal breast epithelial MCF10A cells 
Over the past few years, it has been demonstrated that cells that undergo EMT 
also acquire stem cell-like properties [148]. We decided to investigate this 
possibility in MCF10A Epn3-overexpressing cells. To do so we took advantage of 
a protocol that has been recently developed in our lab to isolate and identify 
mammary stem cells within a bulk population [136].  
The approach we have used relies on two functional properties of 
mammary stem cells: 1) their relative quiescence and slow proliferation rate; 2) 
their capacity to survive and proliferate in an anchorage-independent manner, 
giving rise to clonal spheroids, named “mammospheres” [149-151]. The stem cells 
present in a bulk population are identified based on their ability to retain the 
lipophilic fluorescent dye PKH26, which is instead progressively lost by dilution in 
the highly proliferating differentiated/precursor cells [151]. In this experimental 
procedure, epithelial cells are labeled with PKH26 and plated in suspension 
culture to allow stem cells present in the cellular population to give rise to a clonal 
mammosphere. In most cases, each mammosphere is characterized by the 
presence of one PKH26-labeled stem cell located at the center of the 
mammosphere, while the existence of more than one PKH26-labeled cell suggests 
the presence of a cellular aggregate rather than a functional structure.  
Taking advantage of this approach, we performed a mammosphere 
formation assay using MCF10A pBABE, pBABE-Epn3, pBABE-Epn1 and pBABE-
mTwist cells. We observed that pBABE-Epn3 cells show 2-fold increase in the 
number of mammospheres formed in vitro than pBABE and pBABE-Epn1 cells 
(Figure 18A,B). Similar results were also obtained upon Twist overexpression that 
induces more than 2-fold increase of number of mammospheres (Figure 18). This 
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result agrees with previous studies in the literature demonstrating that Twist 
overexpression increases the mammosphere-forming efficiency of mammary 
epithelial cell lines [148]. 
Based on these data, we conclude that Epn3 overexpression is able to 
induce some stem cell-like properties like the capacity to form mammospheres in 
vitro. Together these results indicate that Epn3 is capable of inducing EMT and the 
EMT-associated stem-like behavior in normal epithelial cells. Epn3-induced EMT 
might therefore contribute to the observed increase in invasiveness and tumor 
aggressiveness in breast cancer through the expansion of the stem cell 
compartment. 
 
 
 
 
Figure 18 | Mammosphere formation assay of normal epithelial MCF10A cells  
A) Mammosphere formation assay was performed with MCF10A pBABE, pBABE-
Epn1, pBABE-Epn3 and pBABE-mTwist cells by trypsinizing cells and labeling 
them with PKH26 dye. Cells (4,000) were plated in suspension in polyHEMA-
coated 6-multiwell plates in quadruplicates. Results are shown as the mean 
number of mammospheres per well ± SD of two independent experiments 
performed in quadruplicate. Asterisks indicate a p-value < 0.05. B) Representative 
bright-field microscopy images of mammospheres formed by MCF10A expressing 
either empty vector (pBABE), Epn1 Epn3 or mTwist. The boxed areas are 
magnified on the right and show a mammosphere derived from one PKH26-
positive stem cell. Magnification 4x. Scale bar 100µm. 
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2.2.3 Epn3 overexpression induces EMT and increases the in vivo 
tumorigenic potential of breast tumor HCC1569 cells 
We have found that Epn3 expression is associated with poor prognosis human 
breast tumors (Section 1.1 and section 1.2) and that Epn3 ablation in breast tumor 
BT474 cells, carrying EPN3 gene amplification, is able to impair tumorigenic 
potential both in vitro and in vivo (Section 2.1.1 and 2.1.2).  
To investigate if the overexpression of Epn3 in normal mammary epithelial 
MCF10A cells could induce a tumorigenic phenotype, we took advantage of the 
engineered MCF10A cells overexpressing Epn3 (pBABE-Epn3). We tested the 
capacity of these cells to grow in an anchorage-independent manner - a hallmark 
of cell transformation - by plating cells in a semi-solid medium. Our results showed 
that none of the cell lines tested (pBABE, pBABE-Epn1, pBABE-Epn3, pBABE-
mTwist) formed colonies (Figure 19). On the contrary, the cell line used as positive 
control of the assay, MCF10A overexpressing the activated form of HER2 (Neu-T), 
was able to form colonies in semi-solid medium as described in the literature [152] 
(Figure 19).  
Given this result, we decided to move towards a tumorigenic breast cell line 
that could be more prone to transformation. We chose as a model system the 
breast tumor cell line HCC1569 since this cell line shows low basal levels of Epn3, 
similar to the ones observed in MCF10A cells (Figure 20A). HCC1569 cells were 
infected with a lentiviral vector expressing Epn3 (pLVX-Epn3) and reached levels 
of Epn3 overexpression comparable to those of MCF10A pBABE-Epn3 cells 
(Figure 20A). HCC1569 cells infected with empty vector (pLVX) were used as 
control.  
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Figure 19 | Effect of Epn3 overexpression on anchorage-independent growth 
of normal mammary MCF10A cells 
The anchorage-independent growth of MCF10A-infected cells was assessed using 
the soft agar assay. Cells (20,000) were plated in 6-well culture plates in a medium 
containing 0.3% agar. After 3 weeks in culture, the formation of colonies was 
evaluated by bright-field microscopy. Representative bright-field microscopy 
images are shown. Magnification 10x. MCF10A cells overexpressing Neu-T were 
used as positive control.  
 
 
 
By performing WB analysis, we confirmed that also in the case of HCC1569 
cells, Epn3 overexpression caused upregulation of the mesenchymal markers N-
cadherin and vimentin (Figure 20B). Besides changes in mesenchymal markers 
expression, HCC1569 cells underwent a dramatic change in cell morphology upon 
Epn3 overexpression: while control cells formed very compact colonies, Epn3-
overexpressing cells became more elongated and formed very disorganized 
colonies (Figure 20C), thus recapitulating the EMT phenotype already observed in 
MCF10A overexpressing Epn3. 
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Based on these in vitro observations, we investigated the tumorigenic 
potential of HCC1569 cells in vivo. 1*106 HCC1569 pLVX-Epn3 and control cells 
were orthotopically injected into the inguinal mammary fat pad of NOD/SCID 
female immunocompromised mice. As a control, cells (HCC1569 pLVX) were 
injected into the contralateral mammary gland. Remarkably, Epn3-overexpressing 
cells formed tumor masses with increased growth rate that were ~2-fold bigger 
than the ones originated by control cells (Figure 21A,B). To assess the Epn3 
expression levels on the tumors extracted from the mammary gland, we 
dissociated them into cells and performed WB analysis. We observed that the 
Epn3 overexpression levels similar to those displayed by the parental HCC1569 
cells in vitro (Figure 21C).  
Thus, we conclude that Epn3 overexpression in breast tumor cells HCC1569 
is able to induce EMT and to increase their tumorigenic potential in vivo. 
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Figure 20 | In vitro functional characterization of Epn3 overexpression in 
HCC1569 cells 
HCC1569 cells were infected with lentiviral vector expressing Epn3 (pLVX-Epn3) 
and empty vector as control (pLVX). MCF10A cells were infected with retroviral 
vector pBABE (empty vector) and pBABE-Epn3. A) Epn3 expression was 
evaluated by WB analysis in HCC1569 after lentiviral infection and was compared 
with the expression of Epn3 in MCF10A pBABE-Epn3. Epn3 was detected using 
VI31 antibody. Both short and long exposure blots are shown (s.e. and 
l.e.,respectively). Tubulin was used as loading control. B) The expression of N-
cadherin, Vimentin, E-cadherin and Epn3 in HCC1569-infected cells was 
assessed by WB analysis. C) The morphology of HCC1569 cells expressing 
control vector pLVX or pLVX-Epn3 was assessed by phase contrast microscopy. 
Representative images are shown. Magnification 20x. 
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Figure 21 | Effect of Epn3 overexpression on in vivo tumor growth of 
HCC1569 cells 
Mammary tumors were generated by injecting HCC1569 Epn3-overexpressing 
(pLVX-Epn3) cells and control (pLVX) cells (1*106) into the inguinal mammary fat 
pads of female NOD/SCID IL2 gamma-chain null mice. Tumors were grown for 43 
days before being explanted. A) Kinetic evaluation of HCC1569 pLVX-Epn3 and 
pLVX tumor growth. Tumor volume was assessed by in vivo caliper 
measurements at the indicated time points after injection. Asterisks indicate mean 
p-value < 0.05 (*) and < 0.01 (**) compared to pLVX. B) The distribution of tumor 
volume of HCC1569 pLVX-Epn3 and pLVX is reported in a box-plot. 
Representative images of tumor outgrowths are reported below the chart. C) The 
expression of Epn3 in mammary tumors was assessed by WB analysis using an 
anti-Epn3 VI31 antibody. Vinculin was used as loading control. Results are 
representative of 2 experiments (n=8) and represent the mean± SEM.  
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3 Dissection of the molecular mechanism responsible for Epn3-
induced EMT  
3.1 Epn3 overexpression increases basal and TGFβ-induced E-cadherin 
internalization in MCF10A normal breast epithelial cells 
We have found that Epn3 overexpression in MCF10A is able to induce an EMT 
phenotype characterized by a decrease in E-cadherin protein levels and the 
rearrangement of cell-cell junctions (see section 2.1).  
 E-cadherin is the prototypical member of the classical cadherin superfamily 
and it represents the major component of the adherent junctions (AJs), providing 
cell-cell adhesion through Ca2+-dependent, homophilic binding between molecules 
on adjacent epithelial cells (reviewed in [153]). Loss of E-cadherin expression is 
considered a prototypical marker of EMT and a strong rearrangement of E-
cadherin-mediated cellular junctions occurs during tumor invasion and metastasis 
[154]. Multiple mechanisms have been described to underlie the loss of E-cadherin 
function and they comprise both transcriptional and post-translational regulation of 
E-cadherin. Besides E-cadherin regulation at the genomic level (reviewed in 
[155]), another mechanism known to disrupt E-cadherin’s adhesive function and 
promote tumor aggressiveness is the endocytic trafficking with consequent 
downmodulation of surface E-cadherin (reviewed in [156]). 
Given the established role of the epsin protein family in endocytosis, we 
tested the hypothesis that Epn3 could have a role in E-cadherin internalization, 
thus altering its turnover from the cell surface. To this aim, we set up an E-
cadherin internalization assay in vivo using an antibody recognizing the 
extracellular domain of E-cadherin (see Material and Methods for details). Briefly, 
the antibody is allowed to bind to cells for 1h at 4°C, a temperature at which 
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endocytosis is inhibited. When cells are transferred at 37°C, E-cadherin 
internalization can occur and the effects of Epn3 overexpression on E-cadherin 
endocytosis assessed.  
Many different pathways have been demonstrated to regulate E-cadherin 
internalization during EMT. One of those, the TGFβ pathway, appears to be a key 
regulator of cadherin turnover during EMT and to induce E-cadherin endocytosis 
[157]. To test whether Epn3 could potentiate TGFβ-dependent E-cadherin 
endocytosis, we performed the E-cadherin internalization assay in MCF10A 
pBABE and pBABE-Epn3 cells stimulated with TGFβ for 90 and 180 minutes. In 
control cells, we noticed that basal E-cadherin turn-over (in absence of any stimuli) 
was very slow and that no significant downregulation from the cell surface 
occurred (Figure 22A, left panel). On the contrary, in non-stimulated Epn3-
overexpressing cells, E-cadherin was partially downregulated at time zero, an 
observation compatible with the anti-E-cadherin staining previously observed at 
the cell-cell junctions (Figure 16C), suggesting that basal E-cadherin turnover is 
accelerated upon Epn3 overexpression (Figure 22A, right panel). After the 
temperature shift from 4°C to 37°C, control cells stimulated with TGFβ for 90 
minutes showed E-cadherin staining at the PM (Figure 22A, left panel, middle 
lane); after 180 minutes of TGFβ stimulation, we observed a partial internalization 
of E-cadherin in control cells (Figure 22A, left panel, bottom lane). In Epn3-
overexpressing cells, E-cadherin was efficiently internalized already at 90 minutes 
of TGFβ stimulation and, after 180 minutes, all cells accumulated E-cadherin in the 
intracellular compartments without any residual PM staining (Figure 22A, right 
panel). Thus, our data suggest that Epn3 overexpression increases TGFβ-induced 
E-cadherin internalization in MCF10A cells. 
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We also performed co-localization studies of E-cadherin and Epn3 in 
MCF10A cells and the results are reported in Figure 22B. In a steady state 
condition (time 0, non-stimulated), both E-cadherin and Epn3 were localized at the 
cell surface and even though they did not co-localize entirely, Epn3 seems to be 
juxtaposed to E-cadherin. This observation is compatible with the fact that Epn3 
has a cytoplasmic epitope while E-cadherin presents an extracellular one (Figure 
22B, first lane). Importantly, after 90 and 180 minutes of TGFβ stimulation, both 
Epn3 and E-cadherin were delocalized from the PM to intracellular compartments 
with many sites of co-localization (Figure 22B, see yellow dots). 
In conclusion, our results show that overexpression of Epn3 positively 
regulates TGFβ-dependent E-cadherin internalization and that Epn3 co-traffics 
with E-cadherin along the endocytic route. These observations suggest that Epn3 
promotes EMT and tumor aggressiveness via its role as an endocytic protein on E-
cadherin trafficking.  
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Figure 22 | Effect of Epn3 overexpression on TGFβ-induced E-cadherin 
internalization in normal mammary epithelial MCF10A cells 
For the E-cadherin internalization assay, cells were incubated with anti-E-cadherin 
antibody (HECD-1, Abcam) at 4oC in PBS for 1h and then fixed in 4% PFA (0 min). 
For other samples, immediately after incubation at 4oC, medium containing serum 
and TGFβ (5ng/mL) was added to the cells at 37oC for 90 and 180 minutes (90 
min and 180 min). After incubation with TGFβ, cells were fixed in 4% PFA. A) 
Immunofluorescence analysis of E-cadherin (red) and Epn3 expression (green). 
Nuclei are counterstained with DAPI (blue). White asterisks indicate cells lacking 
E-cadherin staining. 
 B) Co-localization of Epn3 and E-cadherin was evaluated by immunofluorescence 
analysis during E-cadherin internalization assay described above. The boxed 
areas are magnified on the right to better observe co-localization sites (yellow 
dots).  
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3.2 Epn3 overexpression increases TGFβ signaling and response in normal 
breast epithelial MCF10A cells 
The observation that Epn3 potentiates TGFβ-dependent trafficking of E-cadherin, 
made us wonder if Epn3 overexpression could also directly regulate TGFβ 
signaling pathway and/or cooperate with TGFβ signaling in the establishment of 
EMT. We reasoned that, since TGFβ pathway is frequently subverted in cancer 
and is known to promote tumor progression by inducing EMT in mammary 
epithelial cells, this pathway could be involved in Epn3-dependent EMT (reviewed 
in [158]). In agreement with this possibility, we found that Epn3-overexpressing 
cells display an increase in the transcript levels of TGFβ receptors (TGFBR1 and 
TGFBR2) and ligands (TGFB1 and TGFB2) are significantly increased compared 
to control cells, as assessed by Q-PCR analysis (Figure 23) Moreover, TGFB2 
mRNA levels further increase after stimulation with TGFβ (Figure 23). These 
observations unveil the existence of a transcriptional positive feedback loop 
required to further sustain the EMT phenotype of Epn3-overexpressing cells. 
  We thus investigated a possible cooperation between Epn3 and the TGFβ 
pathway. The TGFβ signaling pathway is well characterized and involves the 
recruitment and phosphorylation of serine-threonine kinase receptors, which in 
turn induce the phosphorylation of Smad proteins (Smad2 and Smad3). Once 
activated, Smad proteins are able to form multiprotein complexes and induce the 
transcription of target genes that are usually considered as EMT markers, 
including the transcription factor Snail and N-cadherin (reviewed in Massague 
2005). To test our hypothesis, we stimulated Epn3-overexpressing and control 
MCF10A cells with TGFβ for extended times (30’-90’-6h-12h-24h) in order to 
follow activation of “early” signaling targets (i.e. phosphorylation of Smads) as well 
as “late” transcriptional response (i.e. Snail, N-cadherin), by WB and Q-PCR 
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analysis (Figure 24A,B). The results indicated that in Epn3-overexpressing cells 
there was a sustained activation of TGFβ signaling, as evidenced by the presence 
of a second peak phosphorylation of Smad proteins (Figure 24A) and a more 
sustained activation of the downstream target Snail (Figure 24A). Furthermore, 
pBABE-Epn3 cells, which express high basal levels of N-cadherin, showed a 
significantly higher activation of N-cadherin after TGFβ stimulation (Figure 24A-B). 
In contrast, in control cells the activation of N-cadherin expression is only slightly 
detectable at very late time points after TGFβ stimulation (Figure 24A,B). These 
data indicate that Epn3 is able to sustain TGFβ signaling and increase TGFβ-
dependent transcriptional programs responsible for the establishment of EMT. 
Indeed, the combination of TGFβ stimulation and Epn3 overexpression further 
enhanced the invasion potential of MCF10A cells in matrigel invasion assay 
(Figure 25). 
Altogether these data suggest that Epn3 is able to increase the expression 
of TGFβ signaling components that could act by enhancing and sustaining a 
mesenchymal state and invasiveness.  
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Figure 23 | Analysis of TGFβ receptor and ligands mRNA levels in MCF10A 
cells 
MCF10A pBABE and pBABE-Epn3 cells were stimulated with TGFβ (0.3 ng/mL) 
for 30 and 90 minutes or cultured without stimuli (-). Transcript levels of TGFβ 
receptor type I (TGFBR1), type II (TGFBR2) and TGFβ ligands (TGFB1 and 
TGFB2) were evaluated by Q-PCR analysis. Data are normalized on the 
housekeeping gene 18S and are expressed as fold-change relative to the non-
stimulated MCF10A pBABE cells (-). Results represent the mean ± SD of two 
experiments performed in triplicate.  
 
0
2
4
6
8
10
12
14
16
- 30' 90' 6h 12h 24h - 30' 90' 6h12h 24h
N-cadherin 
pBABE pBABE-Epn3
Snail
Epn3
30’ 90’ 6h 24h12h 30’ 90’ 6h 24h12h
pB
AB
E
pB
AB
E-E
pn3
pBABE pBABE-Epn3
TGF?
Tubulin
N-cadherin 
P-Smad3
P-Smad2 
- -
TGF?
A B
Re
lat
ive
 m
RN
A 
lev
ele
no
irm
ali
ze
d 
on
 1
8S
 a
nd
 p
BA
BE
 -
 
 
Figure 24 | Analysis of the effect of Epn3 overexpression on the TGFβ 
pathway 
A) MCF10A pBABE and pBABE-Epn3 cells were stimulated with TGFβ (0.3 
ng/mL) for the indicated time points. Expression of phosphorylated Smad2 (P-
Smad2), phosphorylated Smad3 (P-Smad3), Snail, N-cadherin and Epn3 was 
evaluated by WB analysis. Tubulin was used as a loading control. B) N-cadherin 
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transcript levels in MCF10A pBABE and pBABE-Epn3 cells after stimulation with 
TGFβ (0.3ng/mL) were measured by Q-PCR. Data were normalized to the 
housekeeping gene 18S and are expressed as fold-change relative to the pBABE 
control cells non-stimulated with TGFβ (−). Results represent the mean ± SD of 
two experiments performed in triplicate. 
 
 
 
                   
50µm
0
0,04
0,08
0,12
0,16
pBABE pBABE-Epn3
 
*-TGF?+TGF?
Ce
ll d
en
sit
y A
U 
(A
BS
 5
95
nm
)
 
 
Figure 25 | Epn3 overexpression increases TGFβ−induced invasion potential 
of normal mammary epithelial MCF10A cells 
Matrigel invasion assay was performed with pBABE and pBABE-Epn3 cells by 
plating 4,000 cells in the top chamber of a transwell on a layer of growth-factor 
reduced Matrigel. The bottom chamber contained culture medium supplemented 
with TGFβ (0.3ng/mL). After 24 h of incubation cells that had invaded into the 
Matrigel layer were stained with crystal violet. Membranes stained with crystal 
violet were then dissolved in acetic acid and absorbance was measured at 595nm. 
Bar graph reports mean absorbance at 595nm ± SD of 2 experiments performed in 
triplicate. Asterisk indicates a p-value < 0.05 (*). Representative images are shown 
below the graph. Magnification 20x. 
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3.3 Blocking of TGFβ signaling reverts Epn3-induced EMT phenotype in 
normal mammary epithelial MCF10A cells 
Given the observations above described, we tested whether the Epn3-induced 
EMT phenotype is indeed dependent of TGFβ signaling. To this aim, we used 
shRNA oligos to transiently silence both TGFβ receptors (TGFβ type I and TGFβ 
type II receptors) in MCF10A pBABE-Epn3 and control cells. A scramble shRNA 
oligo was used as negative control. As assessed by Q-PCR analysis, ablation of 
these two receptors was efficient when KD was done singularly (TGFBR1 KD and 
TGFBR2 KD) and when it was performed in combination (TGFBR1+2 KD; Figure 
26A). After ablation of TGFβ receptors, we observed an almost complete reversion 
of EMT phenotype in MCF10A Epn3-overexpressing cells. Indeed, N-cadherin and 
vimentin expression was reduced upon TGFβ receptors silencing, as assessed by 
WB and Q-PCR analysis (Figure 26B,C). Moreover, ablation of TGFβ receptors 
also caused a complete reversion of the morphology of Epn3-overexpressing cells 
from a fibroblast-like shape into an epithelial and well-rounded one (Figure 26D). 
Nevertheless, to exclude potential off-target effects of transient silencing 
experiments, we decided to confirm these results by using a chemical inhibitor of 
TGFβ signaling. We used the inhibitor LY2109761 that selectively blocks the 
kinase activity of TGFβ receptor type I and type II, thus inhibiting Smad proteins 
phosphorylation [159, 160].  
Our results show that treatment of MCF10A Epn3-overexpressing cells with 
LY2109761 for 72h was able to decrease the expression of N-cadherin and 
vimentin at basal levels in comparison with control cells (Figure 27A,C). We also 
stimulated cells with TGFβ for 90 minutes after treating cells with the inhibitor and 
then evaluated the activation of Snail protein. We confirmed that the inhibition 
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induced by LY2109761 was effective since we did not observe any activation in 
Snail expression after TGFβ stimulation (Figure 27B).  
In conclusion, through both a genetic and a chemical approach, we have 
demonstrated that the blockage of TGFβ signaling reverts the EMT phenotype 
induced by Epn3 in MCF10A cells.  
 
 
Figure 26 | Analysis of the effect of TGFβ receptor silencing in MCF10A 
Epn3-ovexpressing cells 
MCF10A pBABE and pBABE-Epn3 cells were transiently transfected with shRNA 
targeting TGFβ receptor type I (TGFBR1 KD) or type II (TGFBR2 KD). Transient 
transfection of both shRNA was also performed (TGFBR1+R2 KD). A shRNA with 
a scramble oligo was used as negative control (Scramble).  A) The efficiency of 
the silencing of TGFβ receptor type I and II was assessed by Q-PCR analysis. 
Data are normalized on the housekeeping gene 18S and are expressed as fold-
change relative to the pBABE cells transfected with the scramble oligo . Results 
represent the mean ± SD of two experiments performed in triplicate. B) The 
expression of N-cadherin, vimentin, E-cadherin and Epn3 was evaluated by WB 
analysis using the following antibodies. Tubulin was used as loading control.  
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C) N-cadherin and vimentin transcript levels were evaluated by Q-PCR analysis. 
Data are normalized on the housekeeping gene 18S and are expressed as fold-
change relative to the pBABE scramble cells. Results represent the mean ± SD of 
two experiments performed in triplicate. D) The morphology of MCF10A pBABE-
Epn3 cells transfected with scramble oligo or oligos targeting TGFβ receptor type I 
(TGFBR1 KD) or type II (TGFBR2 KD), or both TGFβ receptor type I and type II 
(TGFBR1+R2 KD) was assessed by phase contrast microscopy. Representative 
images are shown. Magnification 4x. 
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Figure 27 | Analysis of the effect of TGFβ receptors inhibitors in MCF10A 
Epn3-ovexpressing cells 
MCF10A pBABE and pBABE-Epn3 cells were treated with TGFβ receptor kinase 
inhibitor LY2109761 (5µM) for 72h. DMSO treatment was used as negative control 
(-). A) The expression of N-cadherin and vimentin was assessed by WB analysis. 
Tubulin was used as loading control. B) The effect of LY2109761 was evaluated 
by stimulating MCF10A pBABE and pBABE-Epn3 cells with TGFβ (0,3ng/mL) for 
90 minutes. The expression of Snail protein was assessed by WB analysis. 
Tubulin was used as loading control. C) N-cadherin and vimentin transcript levels 
were evaluated by Q-PCR analysis. Data are normalized on the housekeeping 
gene 18S and are expressed as fold-change relative to the non-treated pBABE 
cells (-). Results represent the mean ± SD of two experiments performed in 
triplicate. 
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DISCUSSION 
1 Epn3 as novel prognostic marker in breast cancer 
1.1 Epn3 expression is associated with poor prognosis in breast cancer 
The present clinical management of breast cancer patients relies on the availability 
of robust prognostic and predictive factors, which are used to stratify patients and 
ensure they receive optimal treatment. In the last decade, breast cancer research 
was dominated by the introduction of gene expression profiling techniques aimed 
at the identification of specific molecular signatures that can predict tumor 
behavior and response to therapy (reviewed in [122].  
However, many prognostic and predictive gene expression profiles that 
have been developed (see Introduction, section 3.3) have found poor clinical 
application because of difficulties in the standardization of procedures, high costs 
and little improvement over the traditional breast cancer markers. One other factor 
contributing to the slow introduction of these signatures in the clinic might also be 
the insufficient knowledge on the biological function of some of the genes included 
in these profiles. This lack of knowledge makes unclear which clinical 
characteristics are these signatures measuring. A good option to overcome this 
limitation would be, thus, to select few novel biomarkers within a molecular 
signature that retain the prognostic power of the signature and to assess the 
expression of these biomarkers in large patient cohorts using rapid, standardized 
and low cost tests, such as IHC assays, which are routinely used in the clinical 
setting to assess the expression of the molecular markers currently applied to the 
stratification of cancer patients (e.g., HER2, ER and PgR). 
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In a preliminary unpublished study performed in our lab, a gene expression 
profiling analysis of node-negative human breast tumor samples originated a gene 
signature associated with metastatic relapse in breast cancer patients, which 
included the endocytic protein Epn3. This first observation suggested that Epn3 
transcript levels could be considered a prognostic factor associated with high risk 
of disease recurrence and metastasis.  
To clearly establish Epn3 as prognostic biomarker in breast cancer, we 
analyzed the expression of Epn3 by IHC on large cohorts of breast cancer 
patients. We found that high Epn3 expression is significantly associated with 
traditional markers of aggressive breast cancer. Furthermore, regression analysis 
revealed that Epn3 expression could predict the risk of disease recurrence and 
death up to 10 years after surgery. Interestingly, these results were confirmed also 
in the subpopulation of HER2-negative patients, indicating that the role of Epn3 in 
breast cancer might be independent of HER2.  
The HER2 gene is amplified and leads to protein overexpression in 
approximately 18-30% of human breast tumors [138, 161]. Many studies have 
identified HER2 amplification and protein overexpression as a poor clinical 
outcome biomarker in breast cancer patients [124, 138]. Targeted therapies have 
been developed to specifically treat breast cancer patients carrying HER2 
amplification. Trastuzumab (Herceptin) is a humanized recombinant antibody 
against HER2 and it represents the first choice therapy in HER2-positive breast 
cancer cases [162]. However, a large portion of metastatic HER2-positive breast 
cancer patients has acquired resistance to trastuzumab [163]. Since we have 
found that Epn3 overexpression can correlate also with HER2-positive status, 
Epn3 might represent an additional target to overcome the resistance 
phenomenon in these patients carrying both Epn3 and HER2 overexpression. On 
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the other hand, our findings showing that Epn3 can retain its prognostic value 
independently of HER2 suggest Epn3 as a possible marker to be targeted in 
HER2-negative patients.  
Additionally, we have found that Epn3 expression is significantly associated 
with poor prognosis Luminal B and triple-negative tumors. Both these molecular 
tumor types are of particular interest to the breast cancer research community 
since no systematic targeted therapies have been yet developed for these cancer 
subtypes. In the case of triple-negative breast cancer, poor prognosis results from 
the absence of expression of all three key receptors deregulated in breast cancer - 
ER, PgR and HER2 - and, thus, from the impossibility to develop targeted 
therapies [111]. Luminal B cancers are ER-positive tumors with aggressive 
behavior, high proliferative index and poor clinical outcome [111]. Despite the 
expression of estrogen receptors, the driver pathway of malignancy in the Luminal 
B subtype does not seem to be the estrogen pathway. Indeed, recent clinical trial 
studies have considered targeting alternative pathways, including EGFR-
dependent pathway with the drug gefitinib [164], and PI3K/Akt/mTOR with the drug 
everolimus [165]. Nevertheless, many efforts are needed to find new biomarkers to 
define new-targeted therapies for luminal B breast cancer patients.  
In conclusion, we have clearly established Epn3 as a novel biomarker in 
breast cancer, able to stratify breast cancer patients with poor clinical outcome. 
Since we have set up the experimental conditions to exploit the monoclonal anti-
Epn3 antibody, previously produced in our lab, to detect Epn3 expression by IHC, 
one possibility could be to develop clinical test to assess Epn3 expression in 
breast cancer patients.  
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1.2 EPN3 gene is amplified in human breast tumors: “it can live with or 
without HER2” 
 Gene amplification is one of the most frequent mechanisms of oncogene 
activation in breast cancer. Of note, EPN3 gene is located on chromosome 17 in 
the 17q21 region, relatively close to the HER2 gene that is located in the 17q12 
region. It is known that the amplification of the 17q12-q21 chromosomal region is 
the most common mechanism for HER2 activation in breast cancer and that it 
leads to the simultaneous activation of several other genes besides HER2 [140, 
141]. Since co-amplified and co-activated genes may have an impact on disease 
progression and clinical behavior of HER2-positive tumors, several studies have 
sequenced the commonly amplified region surrounding HER2 gene. These studies 
delineated a minimal common region of about 300kb, the HER2 amplicon ‘core’, 
that includes a set of co-amplified and overexpressed transcripts from the 17q12-
21 region [140, 141]. Some of these genes have been investigated for their 
oncogenic potential in breast cancer. For instance, knockdown of two genes 
included in the amplicon ‘core’, GRB7 and STARD3, decreased cell proliferation 
and cell-cycle progression of breast tumor cell lines harboring HER2 amplification, 
suggesting that their amplification and overexpression may contribute to 
tumorigenic phenotype of these cells [166].  
To this regard, it is worth mentioning that the EPN3 gene is located about 
12Mb away from the minimal chromosomal region surrounding HER2 and it is not 
among the genes of the 17q12-21 amplicon frequently amplified with HER2. Of 
note, Curtis et al recently analyzed copy number, sequence changes and gene-
transcription rates in approximately 2,000 breast cancers encompassing all known 
types. They defined some regions of sequence amplification or deletion that 
deregulate genes that are likely to be involved in the pathophysiology of breast 
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cancer [142]. Interestingly, EPN3 is among those genes away from HER2 
amplicon that are amplified independently from HER2 and that could represent 
novel ‘driver’ cancer genes.  
We have found that the EPN3 gene is amplified in breast tumors. By 
performing FISH analysis on 281 human breast tumor samples, we found that 
EPN3 is amplified in about 18% of breast tumors analyzed. Importantly, even 
though EPN3 gene amplification can correlate with HER2 gene amplification, 
about 50% of the EPN3 amplified cases did not display HER2 co-amplification.  
Our results are in line with EPN3 amplification data made available by the 
Tumor Cancer Genome Atlas (TCGA) consortium that confirmed EPN3 gene 
amplification in almost 7% of all breast cancer patients, with 50% of the cases 
showing co-amplification of HER2 gene (Comprehensive molecular portraits of 
human breast tumors, Nature 2012) (Figure 28). The slight difference between 
TCGA data on EPN3 amplification and our results (7% in TGCA vs. 18% in our 
experiments) might be due to the different techniques used to detect gene 
amplification (Comparative Genome Hybridization-CGH in the TGCA vs. FISH in 
our experiments). Nevertheless, in both studies EPN3 is co-amplified with HER2 in 
approximately 50% of the cases. Thus, we can envision that Epn3 could confer an 
additive advantage to the tumorigenic potential of HER2 in those cases and might 
represent a possible target to improve the treatment response in HER2-positive 
breast cancer patients.  
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Figure 28 | Amplification of the Epsin family and HER2 in breast cancer. 
The data were made available by the Tumor Cancer Genome Atlas study (Nature 
2012). 778 breast invasive carcinoma cases are analyzed. Red squares represent 
amplified cases. Grey squares represent not amplified cases. In this image only a 
certain number of all the analyzed cases are represented due to space limitation, 
but all the altered cases are presented.  
 
 
 
Of note, EPN3 gene amplification seems to be a genetic phenomenon 
specific for breast cancer. Indeed, by looking at gene amplification in the most 
common cancers, EPN3 is significantly amplified only in breast carcinomas 
(Comprehensive molecular portraits of human breast tumors, Nature 2012) (Figure 
29).  In addition, Epn3 seems to be the only member of Epsin family to be 
genetically altered in breast cancer, since neither EPN1 nor EPN2 genes are 
significantly amplified in breast cancer (Figure 28). These observations further 
confirm all the data present in literature suggesting that, differentially from Epn1 
and Epn2, the tight regulation of Epn3 expression in the tissues is peculiar 
phenomenon of this member of the Epsin family [85] (see also Discussion section 
4). 
 Altogether these findings strongly argue that EPN3 amplification could 
represent a driver lesion in breast carcinogenesis that, importantly, can be 
independent from HER2 status in breast cancer patients.  
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Figure 29 | EPN3 amplification in the most common cancer types. 
The data were obtained from cBioPortal for Cancer Genomics. The data are 
represented as percentage of amplification in each cancer type.  
 
1.3 Epn3 is tumorigenic in vitro and in vivo 
The expression of several endocytic proteins has been shown to be altered in 
human cancers and in some cases these alterations have been shown to be 
causative of a tumorigenic phenotype [69, 70].  Our findings that Epn3 expression 
correlates with aggressive disease and that its overexpression is driven by gene 
amplification, prompted us to demonstrate that Epn3 amplification is a driver lesion 
in breast cancer.  
We demonstrated that Epn3 ablation in BT474 cells, which carry EPN3 
gene amplification and protein overexpression, results in a significant decrease of 
the anchorage-independent growth in vitro and of the tumorigenic potential in vivo 
of these cells. Conversely, downregulation of Epn3 expression in MCF7 cells, 
which display low levels of Epn3 expression without any genetic alteration of 
EPN3 locus, does not have the same effect on tumorigenic growth in vitro. To 
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further confirm these results, we plan to evaluate the tumorigenic potential in vivo 
of MCF7 cells upon Epn3 ablation.  
We also show that enforced overexpression of Epn3 in breast tumor cells, 
HCC1569, which express low levels of Epn3, results in increase of their 
tumorigenic potential in vivo. The same effect was not scored in normal mammary 
cells. Indeed, MCF10A Epn3-overexpressing cells were not able to form colonies 
in semi-solid medium - an hallmark of the tumorigenic phenotype. Of note, 
overexpression of Twist, a well-known EMT inducer gene [144], did not induce 
tumorigenic transformation of these cells. These results could be due either to a 
more permissive tumoral background of HCC1569 compared to MCF10A or to the 
fact that HCC1569 cells harbor HER2 amplification and overexpression.  
Indeed, we have demonstrated that the amplification of EPN3 and HER2 
significantly correlates in breast cancer, although the two events can occur 
independently. Importantly, both BT474 and HCC1569 breast cancer cells display 
amplification of the HER2 gene. These cellular model systems are, therefore, 
useful to investigate a possible cooperation of Epn3 and HER2 in breast cancer 
progression. We will therefore investigate in future studies if inhibition of HER2 can 
influence the tumorigenic potential of these cells, which would suggest a 
cooperative effect of Epn3 and HER2 in promoting tumorigenesis. Another 
possibility could be to evaluate the cellular response to HER2 inhibitor treatments 
to understand if Epn3 could have a role in the chemoresistance induced by HER2 
overexpression (reviewed in [163]).  
To further investigate this aspect, it would be interesting to study the 
tumorigenic potential of Epn3 in vivo using mouse models. To this aim, we have 
available in our lab two Epn3 mouse models: i) Epn3-KO mouse model, generated 
by De Camilli’s group [86], that does not show any defects in development, 
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behavior and breeding and that we have backcrossed in an FVB background; ii) 
an inducible Epn3-KI mouse model generated in house. These models could be 
crossed with HER2-driven breast cancer models, such as MMTV-HER2 mice 
[167], and will allow us to find whether Epn3 plays a role in HER2-driven 
tumorigenesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
111 
2 Epn3 overexpression induces EMT phenotype in mammary 
epithelial cells 
2.1 EMT-like phenotype in Epn3 overexpressing cells as a mechanism for 
cancer progression 
Tumorigenesis is a multistep process in which the accumulation of genetic 
alterations drives the transformation of normal cells that progressively acquire self-
sufficiency in growth signals, unlimited replicative potential, resistance to cell death 
signals, leading ultimately to the activation of invasive and metastatic programs 
(reviewed in [49]). 
 The work described in this thesis has demonstrated that, by manipulating 
Epn3 expression in breast tumor cell lines, we can influence their tumorigenic 
growth both in vitro and in vivo. In addition, we have found that enforced Epn3 
overexpression in normal MCF10A cells induces an EMT phenotype characterized 
by decreased expression of the epithelial marker E-cadherin and rearrangement of 
adherent cellular junctions. Moreover, we observed the upregulation of 
mesenchymal markers, N-cadherin and vimentin, and an increase in cell 
invasiveness. Importantly, this effect was reiterated in breast tumor HCC1569 
cells, thus confirming that Epn3 is able to induce an EMT phenotype even in a 
tumoral background. We demonstrate, therefore, that Epn3 might exert its 
tumorigenic potential by reprogramming cells towards an invasive EMT phenotype.   
During EMT, epithelial polarized cells undergo several biochemical changes 
and become fibroblastoid, mesenchymal and highly motile. This process is 
characterized by: i) loss of intercellular adhesion (E-cadherin); ii) upregulation of 
mesenchymal markers (vimentin, N-cadherin); iii) acquisition of spindle 
morphology; iv) increase of motility, invasiveness and metastatic capabilities 
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(reviewed in [143, 168, 169]). EMT has emerged as a key process during 
embryonic development and chronic inflammation and fibrosis, as well as cancer 
progression (reviewed in [143]). Indeed, during carcinoma progression, epithelial 
cells detach from the primary tumor and disseminate to distant tissues leading to 
secondary tumors.  
However, it took a long time to recognize EMT as a potential mechanism for 
tumor progression. The major reason for this late recognition is that the 
involvement of EMT in cancer progression has been inferred predominantly from 
in vitro studies. EMT is a challenging process to follow in vivo in human tumors 
mainly because this phenomenon does not occur homogenously across the tumor. 
Indeed, in some cases, EMT takes a long time to occur and the expression of EMT 
markers appears mainly at the invasive front of the tumoral mass (reviewed in 
[170, 171]). Besides, in vitro models are somewhat limited: few carcinoma cells 
showing a well-defined epithelial phenotype can complete EMT in vitro (reviewed 
in [172]). For these reasons, an “EMT-like” term has been proposed to refer to 
epithelial cells that undergo a partial or “metastable” EMT program, which means 
that cells presenting this phenotype exhibit both epithelial and mesenchymal 
features (reviewed in [172, 173]). An “EMT-like” phenotype is consistent with what 
we have observed in the case of Epn3 overexpression in mammary cells and 
could explain why the cells did not completely lose E-cadherin expression while 
concomitantly expressing mesenchymal markers.  
 Breast cancer is considered a heterogeneous disease and gene expression 
studies have identified different molecular subtypes [111, 137]. Of note, it has 
been shown that the EMT signature is observed in the basal-like subgroup of 
breast cancers characterized by unfavorable prognosis, high rate of disease 
relapse and distant metastasis [174]. In agreement, not only we have observed an 
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EMT-like phenotype upon Epn3 overexpression in breast cell lines, but we have 
also found a strong correlation between Epn3 expression and poor prognosis 
breast cancer subtypes, including basal-like tumors. Therefore, it would be 
interesting to perform a meta-analysis on breast cancer expression data to 
uncover a possible association between Epn3 expression and an EMT signature in 
invasive breast carcinomas.  
 
2.2 Epn3: a novel regulator of the network of EMT, stemness and 
endocytosis? 
Despite recent medical advances, including early detection, adjuvant and targeted 
therapies, tumor relapse and resistance to therapy remain the principal causes of 
death in breast cancer patients.  
An emerging hypothesis is that tumor progression is driven by a 
subpopulation of cells, termed cancer stem cells (CSCs), that have the ability to 
self-renew, form tumor spheres in vitro and regenerate tumors in xenotransplant 
systems [175]. Interestingly, several studies have established a crucial link 
between the activation of an EMT program and the acquisition of molecular and 
functional properties of stem cells [148, 176]. Indeed, Mani and colleagues have 
reported that the induction of EMT in immortalized human mammary epithelial 
cells, by ectopic expression of either transcription factors Twist or Snail, results in 
mesenchymal cells with increased ability to form mammospheres in suspension 
culture and increased expression of CSCs markers, such as CD44+/CD24low [148]. 
Since we have found that Epn3 overexpression induces an EMT phenotype 
in normal human mammary epithelial MCF10A cells, we tested the possibility that 
these cells had also acquired some stem cell-like properties. Mammosphere 
formation assays revealed that Epn3 overexpression increases the capacity of 
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these cells to form mammospheres in vitro. Although these experiments were 
performed only in immortalized cells without allowing propagation of 
mammospheres, they suggest a role for Epn3 in the maintenance of the stem cell 
compartment. However, to further confirm these results, we now plan to perform 
mammosphere serial propagation assays in primary mammary stem cells 
overexpressing or not Epn3. In addition, we will also perform experiments in 
normal mammary stem cells to assess whether overexpression of Epn3 can skew 
the mode of stem cell division from asymmetric (typical of a normal stem cell) 
towards a symmetric one (typical of a putative cancer stem cells) [149, 151]. An 
extreme scenario would be one in which Epn3 overexpression reverts progenitor 
cells to a stem cell-like state, as shown in the case of Sox9 and Slug in the work 
from Weinberg’s group [177]. In breast cancer, an increased proportion of CSCs 
within the tumor accompanies malignant progression: poorly differentiated, more 
aggressive breast carcinomas display a higher CSCs number than well 
differentiated, less aggressive tumors [151]. Under these conditions, 
tumorigenesis might depend on the expansion of the CSC compartment resulting 
from the CSCs mode of division being skewed towards a symmetric mode [149, 
151]. Endocytosis is known to play a crucial role in the regulation of the 
asymmetrical cell division and the partitioning of cell fate determinants (reviewed 
in [1, 2]). Therefore, it is possible that alteration of endocytic pathways can lead to 
the deregulation of the asymmetric division program and induce changes in the 
content of CSCs.  
A prominent example is provided by the endocytic protein Numb, which is 
asymmetrical partitioned during the genesis of the sensory organ of Drosophila 
and confers different fates to the two daughter cells originated from the 
asymmetric division of the precursor cell (SOP). It has been proposed that Numb 
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is able to counteract the activity of Notch receptor by inducing its internalization 
and degradation [73, 178]. In breast tumors, Numb expression is frequently lost 
and such loss correlates with poor prognosis and expression of CSCs markers 
([75, 77, 179], which in the light of the findings that poorly differentiated breast 
tumors harbor high CSCs-content means that Numb-negative tumors are less 
differentiated and more aggressive [151]. Numb represents a leading example of 
the strong connection between endocytosis, homeostasis of the stem cell 
compartment and malignancies. 
 We now provide data arguing for another endocytic protein, Epn3, being 
involved in changes in the endocytic matrix that can affect the development of 
naturally occurring malignancies. We can envision a scenario in which Epn3 might 
induce alterations in the CSC homeostasis through EMT, which lead to an 
expansion of the CSC compartment, acquisition of a motile/invasive phenotype 
and malignant transformation. 
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3 A novel endocytic function of Epn3 regulates TGFβ  pathway 
and response  
3.1 Epn3 functions as an endocytic protein in E-cadherin internalization 
We have already discussed that the loss of E-cadherin expression is the 
prototypical marker of EMT and it is considered a crucial step in the transition from 
papilloma to carcinoma [180]. Multiple mechanisms have been described to 
underlie the loss of E-cadherin function and they comprise transcriptional and 
post-translational regulation of E-cadherin. 
Transcriptional repression of the E-cadherin gene is mediated by several 
transcription factors, including Snail, Slug and Twist  [144, 181, 182]. All these 
transcriptional factors are upregulated and activated during EMT processes 
(reviewed in [155]).  
Besides E-cadherin genomic regulation, the endocytic trafficking of surface 
E-cadherin is also required to disrupt its adhesive function and to promote tumor 
aggressiveness (reviewed in [156]. E-cadherin cell entry routes comprise clathrin-
mediated endocytosis [183], caveolae-dependent endocytosis [184] and also 
macropinocytosis [47]. Stimulation with growth factors or induction of EMT can 
regulate E-cadherin endocytosis that results either in recycling or degradation.  
TGFβ appears to be a key regulator of cadherin turnover during EMT, as it 
has been demonstrated that TGFβ and Ras-Raf signaling cooperate in inducing E-
cadherin internalization through CME [157]. 
We have shown here that Epn3 overexpression in normal mammary 
MCF10A cells results in a reduction of E-cadherin protein levels and 
rearrangement of cellular junctions. We have also demonstrated that Epn3-
overexpressing cells display a reduction of E-cadherin staining at the PM that 
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suggests an increase of basal E-cadherin turnover. Importantly, Epn3-
overexpressing cells significantly accelerated TGFβ-induced E-cadherin 
internalization and downregulation from the cell surface. These results suggest a 
cooperative effect of Epn3 and TGFβ in inducing E-cadherin removal from the PM 
and its internalization.  
Of note, E-cadherin forms a complex with catenins localized at the PM, 
including β-catenin. Once E-cadherin is internalized during EMT, β-catenin 
translocates into the nucleus and acts as transcriptional activator together with T 
cell factor (TCF/LEF) complex and regulates the expression of genes considered 
markers of EMT, including Snail family transcription factors [185, 186]. Thus, one 
possibility would be that Epn3 induces a β-catenin-dependent transcriptional 
program. To test this hypothesis, in future studies we plan to score if, upon 
Epn3overexpression, β-catenin is translocated into the nucleus and shows 
increased transcriptional activity. On the other hand, we will investigate whether 
Epn3 interacts directly or in a complex with E-cadherin at the cell surface. One 
possibility might be that Epn3 interacts with E-cadherin in an ubiquitin-dependent 
manner, since E-cadherin can undergo ubiquitination [187] and Epn3 contains 
UIMs. However, testing this hypothesis will require further investigation by 
performing structural function analysis of Epn3.  
In conclusion, our observations suggest that Epn3 is able to induce EMT by 
acting as endocytic adaptor on E-cadherin trafficking.  
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3.2 Epn3-induced EMT phenotype is dependent on TGFβ signaling 
Epn3 overexpression in MCF10A cells causes EMT and these effects are 
mediated to some degree by Epn3-induced upregulation of the expression of 
TGFβ ligands and receptors. Such upregulation sensitizes cells to TGFβ signaling, 
as we detected an increased TGFβ response (Smad-2 and Smad-3 
phosphorylation, upregulation of Snail and of N-cadherin, and invasiveness) in 
Epn3-overexpressing cells.  
TGFβ signaling strongly regulates tumor initiation, progression and 
metastasis. In breast cancer, TGFβ signaling plays a dual role in tumorigenesis. In 
early lesions, TGFβ acts as tumor suppressor through its growth inhibitory effects 
[188]. In contrast, TGFβ promotes metastatic spread in later stages of 
tumorigenesis. In numerous models of breast cancer associated with invasion and 
metastasis, activated TGFβ signaling induces increased aggressiveness. For 
example, in mice overexpressing the Neu oncogene, the concomitant 
overexpression of TGFβ protein increased the number of circulating cancer cells 
and lung metastases [189]. Likewise, ablation of TGFβ signaling in the same 
model decreases the number of lung metastases while also decreasing the latency 
of primary tumor growth, again emphasizing the dual functions of TGFβ in 
tumorigenesis [190]. 
Additionally, clinical evidence suggests that TGFβ ligands are 
overexpressed either at the mRNA or protein level in breast tumors. Intense TGFβ 
immunostaining correlates with disease progression to metastasis in breast 
carcinomas [191, 192]. Moreover, high TGFβ ligands levels correlates with poor 
outcome in breast cancer patients [193].  
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Because TGFβ signaling is a key inducer of the EMT program in a 
tumorigenic context, it is likely that the ability of TGFβ to promote metastasis is at 
least in part due to its ability to induce EMT (reviewed in [194-196]). However, a 
recent paper from Polyak’ s group suggests an alternative mechanism. Expression 
profiling of a population of breast epithelial stem cells showed enrichment in 
transcripts associated with cell motility, angiogenesis and TGFβ pathway, thus 
suggesting a possible role for TGFβ in mammary stem cell maintenance [197]. 
Interestingly, Weinberg’ s group had already demonstrated that mesenchymal 
cells are able to maintain their residence in the mesenchymal–stem cell state by 
ongoing autocrine signaling. The work established that the network of reinforcing 
autocrine loops engages also TGFβ pathway [198].  
Based on the existing wide knowledge on the circuitries between TGFβ, 
EMT and breast cancer, we can speculate that our results suggest a possible new 
role for the endocytic protein Epn3. According to our proposed model, Epn3 acts 
as endocytic protein on E-cadherin trafficking. Downregulation of E-cadherin 
induces an EMT program that involves upregulation of mesenchymal proteins that 
control cell motility and invasion. Among all the activated transcripts, there are 
components of TGFβ signaling, such as TGFβ proteins and receptors that act by 
maintaining and eventually further increasing the EMT state upon stimulation.  
The dependence of the Epn3-induced EMT phenotype on TGFβ in our 
mammary cell system was confirmed by an almost complete reversion of the 
Epn3-induced EMT after treatment with a TGFβR inhibitor or after silencing 
TGFβR. Given these in vitro results, we are now interested in assessing whether 
the ability of Epn3 to increase the tumorigenic potential of breast tumor cells in 
vivo is also dependent on TGFβ. To this aim, we are planning to evaluate whether 
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treatment with TGFβ inhibitor is able to reduce the tumorigenic capacity of breast 
tumor cells upon Epn3 expression in xenografts experiments. 
These observations might have a strong clinic impact. Of note, clinical trials 
with anti-TGFβ agents are ongoing  (reviewed in [196]).  Since TGFβ has a strong 
impact also in cell physiology, due to its function as cytostatic and homeostatic 
function in the cells, it is possible that treatment with anti-TGFβ drugs might have 
to be limited: for example, it might be used against metastases only for certain 
tumors, maybe in limited doses, and in combination with other inhibitors of the 
EMT program.  
In conclusion, if we score some effects on Epn3-driven tumorigenesis by 
treating the mice with TGFβ inhibitors, then we can think to translate these findings 
to the clinical setting by performing some correlations between Epn3 and TGFβ 
signatures in human breast tumor samples. In this scenario, Epn3 could be used 
as marker to stratify breast cancer patients that could benefit from a TGFβ 
inhibiting treatment.  
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4 The physiological role of Epn3 as the missing piece of the puzzle 
Growing evidence suggests that Epn3 is the only epsin family member aberrantly 
expressed under pathological conditions [85], supporting the possibility that it 
might be involved in critical cellular functions.  
The present study has demonstrated that Epn3 is overexpressed in breast 
cancer and that Epn3 overexpression correlates with disease progression. 
Importantly, this pathological role in breast progression seems to be specific for 
Epn3 and not shared by the other members of the epsin family. Indeed, as we 
have already discussed, neither EPN1 nor EPN2 genes are significantly amplified 
in breast cancer (see Discussion, section 1.2 and Figure 28). Additionally, by 
overexpressing Epn1 in breast cell lines we did not observe the EMT-like 
phenotype scored upon Epn3 overexpression (see Results, section 2.2.1), a 
feature that we believe is crucial for cancer progression.  
These observations prompted us to hypothesize that Epn3 might have 
evolved an additional/specialized function, closely linked to molecular pathways 
differentially activated in cancer cells. Amino acid sequence alignment of the Epsin 
family members reveals that all three proteins show high similarity and conserved 
domain organization (about 80% of identity) (Figure 30). Future proteomic and 
structural function studies will help to unveil differences between the epsin family 
members that do not emerge simply from sequence and structural analysis of the 
proteins. On the one hand, we will engineer constructs carrying deletions or point 
mutations in the different functional domains of Epn3 (ENTH, UIM, DPW, Clathrin 
box, NPF) (see also Introduction, section 2.1.1). The resulting mutant proteins will 
be expressed in normal and tumor breast cells and these cells will be tested for 
their ability to undergo EMT as well as in other biological and tumorigenic assays. 
Such assays will probably allow the identification of the domain responsible for the 
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peculiar oncogenic properties of Epn3. On the other hand, we plan to generate 
Epn1-Epn3 chimeric proteins. This approach has the advantage of not being 
biased towards known endocytic functions of epsins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30 | Amino acid sequence alignment of Epn1, Epn2 and Epn3. 
The indicated protein sequences were taken from NCBI-Protein database and 
were aligned using CLUSTALW.  
 146
Figure 37: Amino acid alignment of epsin1, epsin2 and epsin 3.  
The indicated protein sequences (from NCBI-Protein Database) were aligned using 
CLUSTALW.  
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Based on its highly conserved domain structure in comparison to other 
epsins, Epn3 is predicted to be an endocytic protein. This assumption is further 
strengthened by data demonstrating that Epn3 is localized in the endocytic 
compartment and that it interacts with known endocytic/trafficking proteins, such 
as AP2 and clathrin ([86] and our unpublished data). Given the important crosstalk 
that is emerging between endocytosis, signaling and cancer, it is possible that 
Epn3 exerts an oncogenic activity through an endocytosis-based mechanism. We 
have found that Epn3 overexpression in normal breast cells is able to increase E-
cadherin internalization thus inducing EMT-like phenotype and contributing to 
cancer progression.  This effect on E-cadherin trafficking seems to be specific for 
this cargo, since our previous data in the lab demonstrated that Epn3 
overexpression does not influence the trafficking of other cargos, such as EGFR, 
transferrin receptor (TfR) and TGFβ receptor. 
One important unanswered question remains about the physiological role of 
Epn3. Indeed, it would be very interesting to understand whether the function of 
Epn3 as adaptor protein on E-cadherin internalization is a specific oncogenic 
function that cancer cells acquire upon EPN3 gene amplification and protein 
overexpression, or whether Epn3 still retains this endocytic function in cell 
physiology. To address this, we can take advantage of the Epn3-KO mouse model 
previously described by De Camilli and colleagues. Since Epn3-KO mouse does 
not show any particular phenotype, one can think of some overlapping function of 
the other two epsins. However, a more accurate description of this mouse model is 
still missing. It is now clear that Epn3 exerts a role in the migration and invasion of 
breast cell lines and this is in complete agreement with the work that first identified 
Epn3 as a novel transcript upregulated by migrating keratinocytes in cutaneous 
wounds [85]. Therefore, we can use cells derived from Epn3-KO mice (i.e. mouse 
 
 
124 
fibroblast or breast epithelial cells) to perform endocytic assays to confirm the role 
of Epn3 on E-cadherin trafficking also in physiological conditions. Moreover, we 
can also perform biological assays, such as wound healing in vivo assays, to 
understand whether Epn3 is necessary for the migration and reorganization of 
tissues after injury.  
Altogether, these approaches will allow an even more accurate dissection 
of Epn3 role in physiology and cancer. The main possible scenarios are: i) Epn3 
exerts a certain function in physiology that becomes aberrant upon the genetic 
liaison that occurs in breast cancer leading to protein overexpression; ii) Epn3 
protein, when overexpressed due to gene amplification, in a tumoral context 
acquires a novel aberrant function that contributes to tumorigenesis. Both these 
hypotheses are compatible with the fact that Epn3 is expressed at very low levels 
in all normal homeostatic tissues, while it is upregulated almost exclusively in 
pathological conditions, where it can exert its function contributing to malignancy.  
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